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L-type (Cav1.2) voltage-gated calcium channels play critical roles in membrane 
excitability, gene expression, cardiac and smooth muscle contraction. Alternative splicing 
of the pore-forming Cav1.2 α1-subunit (α11.2) provides potent means to enrich the 
functional diversity of the channels. Systematic screening of the human α11.2 gene by the 
transcript-scanning method revealed 19 of the 55 exons were subjected to alternative 
splicing. Among these 19 exons, two novel exons exon 9* and exon 10* were for the first 
time identified in human tissues. Exon 9* was found to be selectively expressed in 
vascular smooth muscle. In addition, inclusion of exon 9* in the α11.2 subunit produced 
channels that activated at more hyperpolarized potentials. However, the properties of 
exon 10* are still unknown. Detailed analyses of the distribution of domain IVS3-IVS4 
splice variants revealed tissue specific and developmental regulation. Interestingly, 
electrophysiological investigations using patch-clamp recording system demonstrates a 
correlation between the longer linker lengths with the more depolarized activation 
potentials occurring in IVS3-IVS4 splice variants. 
The combinatorial usage of alternatively spliced exons in full-length α11.2 
transcript was for the first time analyzed and compared in this study. A total of 64 full-
length exon-combinations have been found in rat heart and aortic tissues based on 10 
alternatively spliced exons. In addition, three distinctive full-length cDNA libraries have 
been generated. Two are from heart which are designated heart 1a-50 and heart 1-50 
cDNA libraries, and one is from aorta, designated aorta 1-50 cDNA library. These 3 
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distinctive cDNA libraries were generated in both SHR and WKY rats giving rise to a 
total of 6 full-length α11.2 cDNA libraries.  
Tissue-specific splicing profiles of α11.2 subunit were first analyzed in heart and 
aortic tissues of the normotensive WKY rats. A distinctive picture emerges where the 
splicing profiles of α11.2 subunits isolated from heart are clearly different from those 
isolated from aorta. The predominant exon-combinations are distinct between those of 
heart and aorta α11.2 transcripts. Interestingly, we were able to generate a heart 1-50 
cDNA library that has not been described and the cellular origin of the transcripts 
requires further experimental verifications. 
Full-length cDNA libraries of the α11.2 subunits from SHR and WKY rats were 
compared to examine possible alterations in utilization of single alternatively spliced 
exons and in combination under a pathological condition. Indeed, the splicing patterns of 
cardiac and aortic tissues isolated from the SHR hypertensive rats were significantly 
altered providing evidence for pathology-induced alternative splicing. It will be of great 
interest to characterize the physiological and pharmacological role of Cav1.2 channels 
containing the novel splice combinations and to assess whether they may be useful as 
potential targets for drug discovery. 
This study provides essential molecular information for understanding the roles of 
Cav1.2 channels in the cardiovascular system. It also demonstrates that alternative 
splicing is a widely used mechanism to diversify the proteomic functions of Cav1.2 
channels. 
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1.1 General introduction of Voltage-gated calcium channels  
Calcium ions (Ca2+) play important roles in cellular signaling and maintaining the 
appropriate concentration of free Ca2+ is critical for controlling many essential cellular 
functions (Carafoli and Klee, 1999). Voltage-gated calcium channels (VGCCs) open 
upon membrane depolarization and provide an elegant means to control the cytosolic 
Ca2+ concentration by allowing rapid influx of Ca2+. The increase in cytoplasmic Ca2+ 
initiates a variety of cellular events like muscle contraction, hormone and 
neurotransmitter release, gene expression, cell motility, membrane excitability and 
fertilization (Fig. 1.1) (Stea et al., 1995; Tsien R. W., 1999; Catterall, 2000). In this 
regard, VGCCs serve as direct links to transduce depolarization signals into the non-
electrical activities that are controlled by excitation (Hille, 2001). Hence, the molecular 
characteristics of VGCCs and their corresponding functional roles are important topics in 
current research. 
VGCCs (except T-types) are hetero-oligomeric complexes consisting of a main 
pore-forming α1-subunit in association with auxiliary β-, α2δ- and/or γ-subunits (Fig. 
1.1) (Catterall, 2000). The α1-subunit supports Ca2+ influx and largely determines 
channel biophysical and pharmacological properties. Ten α1-subunit genes have been 
isolated and characterized. They can be categorized into Cav1, Cav2 and Cav3 families 
according to their phylogenetic relationships. The Cav1 family consists of all the L-type 
calcium channels namely α1S, α1C, α1D and α1F channels; Cav2 family includes P/Q-
type (α1A), N-type (α1B) and R-type (α1E) channels; and Cav3 family comprises the T-
type (α1G, α1H and α1I) channels (Hille, 2001). 
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Fig. 1.1 Physiological effects of rapid influx of Ca2+ through Voltage-gated calcium channels 
(VGCCs). VGCCs (except T-types) comprise the transmembrane pore-forming α1-subunit (Cav 
α1) in association with the β, α2δ and/or γ- subunits. Influx of Ca2+ ions into the cells through the 
VGCCs triggers physiological effects that are dependent on the type and location where the 
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1.2 Voltage-gated calcium channel Cav1.2 and its functions  
Cav1 channels are distinguished from Cav2 and Cav3 channels by their selective 
sensitivity to dihydropyridines (DHPs), phenylalkylamines (PAAs) and benzothiazepines 
(BTZs) and by their characteristic slow inactivating IBa currents (Tsien R. W., 1999; 
Catterall, 2000). Four genes encode Cav1 α1-subunits, CACNA1S, CACNA1C, 
CACNA1D and CACNA1F. Among them, Cav1.2 α1-subunits encoded by the 
CACNA1C gene are widely distributed in heart, brain, smooth muscle and endocrine 
cells. They play an essential role in cardiac muscle contraction, in mediating hormone 
release from endocrine cells (Catterall, 2000; Sinnegger-Brauns et al., 2004), and in 
excitation-transcription coupling for gene expression in neurons and arterial smooth 
muscle (Bito et al., 1997; Cartin et al., 2000; Dolmetsch et al., 2001).  
In cardiac myocytes and arterial smooth muscle cells, Cav1.2 channels are the 
major VGCCs acting as conduits for Ca2+ to pass from the extracellular space into the 
cytoplasm. The critical role that Cav1.2 channels play in cardiovascular function was 
demonstrated acutely by the embryonic lethality of the knock-out mouse in which the 
Cacna1c gene was ablated (Seisenberger et al., 2000). Further support of the essential 
role of Cav1.2 channels was demonstrated by the phenotype of the conditional knock-out 
of Cav1.2 channel expression in murine smooth muscle. The targeted mice developed 
severe hypotension and related smooth muscle dysfunction leading to death one month 
after Cav1.2 channel expression was conditionally ablated in blood vessels (Moosmang et 
al., 2003). 
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1.2.1 Structure of Cav1.2 channel 
The Cav1.2 channel is a complex of three distinct subunits, which are encoded by 
multiple genes. The α1 subunit of ~240 KDa is the largest subunit, and it incorporates the 
conduction pore, the voltage sensor and gating apparatus, and sites for channel regulation 
by second messengers, drugs and toxins. An intracellular β subunit and a transmembrane 
disulfide-linked α2δ subunit complex are components of the Cav1.2 calcium channel (Fig. 
1.1). All these accessory subunits fine-tune the function of the pore-forming α1 subunit 
(Hofmann et al., 1994; Stea et al., 1995; Striessnig, 1999; Catterall, 2000; Ertel et al., 
2000). 
The pore-forming α1 subunit of Cav1.2 (α11.2) consists of four homologous 
domains (I-IV), with each domain containing six transmembrane segments (S1-S6) (Fig. 
1.2). The voltage-sensing mechanism is thought to lie within the S4 segment of each 
domain, where every third or fourth amino acid is a positively charged arginine or lysine 
(Tsien et al., 1991). 
Chapter I Introduction 
 
 




Fig. 1.2 Schematic representation of the Cav 1.2 α1 subunit (α11.2). The α11.2 subunit is 
composed of 4 domains (I-IV), each consisting of 6 transmembrane segments (S1-S6). The S4 
segment is the voltage sensor and lining it is 3-4 positively charged residues. The re-entrant S5-
S6 loop region lines the pore and forms the selectivity filter. Joining the domains are the 




1.2.2 Pharmacology of Cav1.2 channel  
The functional importance of Cav1.2 channels underlines the pharmacological 
significance of their agonists and antagonists. Drugs such as dihydropyridines (DHPs), 
phenylalkylamines (PAAs), benzothiazepines (BTZs) selectively target Cav1.2 calcium 
channels and block the influx of Ca2+ ions (Tomlinson et al., 1993; Striessnig, 1999; 
Tsien R. W., 1999; Catterall et al., 2003). Previous studies have demonstrated that 
residues in domain III segment 5 (IIIS5), domain III segment 6 (IIIS6) and domain IV 
segment 6 (IVS6) determine the binding of DHPs to the Cav1.2 channel, while IIIS6 and 
Chapter I Introduction 
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IVS6 region participate in the binding of PAAs and BTZs (Peterson et al., 1996; 
Hockerman et al., 1997; Striessnig, 1999).   
The modulation of Cav1.2  channels by VGCC blockers is an important 
therapeutic option in the treatment of a variety of disorders including hypertension and 
angina pectoris (Striessnig, 1999; Lacinova et al., 2000). The DHPs are well tolerated and 
are associated with minimal side effects, such as headache, flushing, hypotension, pedal 
edema and are the frequently prescribed antihypertensive drugs (Carter and Saseen, 
2002). In treatment for angina pectoris, VGCC blockers lower arterial pressure by 
reducing peripheral vascular resistance resulting in vasodilatation of the coronary arteries 
to improve myocardial oxygen. Some of these drugs can also reduce heart rate and 
myocardial contractility, thus decreasing oxygen demand and alleviate the angina 
syndromes (Katzung, 2001). 
In therapeutic doses, DHPs can effectively lower blood pressure without 
obviously affecting normal heart functions. One reason could be due to the different 
structures and cellular contents between the two types of muscle cells. Vascular smooth 
muscle cells have significantly less intracellular Ca2+ stores than myocardial cells. Thus 
the smooth muscles rely more on the influx of extracellular Ca2+ to trigger contraction. L-
type Ca2+ channels, mainly Cav1.2 channels, therefore play a major role in the influx of 
Ca2+ in vascular smooth muscles (Wellman and Nelson, 2003). Another reason could be 
due to the structural differences between the pore-forming α11.2 subunits from the two 
muscle cell types. It has been reported that Cav1.2 channels from cardiac myocytes are 
less sensitive to DHPs compared to their counterparts from vascular smooth muscles 
(Welling et al., 1993; Welling et al., 1997). The α11.2 sequences from cardiac and 
Chapter I Introduction 
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smooth muscles are derived from two different promoters, with the final transcripts 
prefixed by exon 1a in cardiac myocytes while by exon 1 in smooth muscle cells (Pang et 
al., 2003). Furthermore, α11.2 from cardiac and smooth muscles have further different 
sequences in the domain I-II loop and the domain IVS3 segment due to alternative 
splicing of α11.2 pre-mRNA (Welling et al., 1993). Welling et al proposed that in 
addition to the known DHPs binding sites located in IIIS5, IIIS6 and IVS6 segments, the 
IS6 segment encoded by alternatively spliced exon 8 in smooth muscles and its mutually 
exclusive counterpart, exon 8a, in cardiac muscles may also participate in the “weak 
affinities” of DHPs to α11.2 channels, and hence contribute to their different 
pharmacology (Welling et al., 1997). 
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1.3 Alternative splicing 
Alternative splicing is the process by which multiple mRNAs can be generated 
from the same pre-mRNA by the differential joining of 5’ and 3’ splice sites. For 
example, exons can be extended or shortened, skipped or included, and introns can be 
removed or retained in the mRNA (Fig. 1.3). In some cases, exons are included in the 
mRNA in a mutually exclusive manner (Black, 2003). 
 
Fig. 1.3 Patterns of alternative splicing. Constitutive sequences present in all final 
mRNAs are gray boxes. Alternative RNA segments that may or may not be included in the 
mRNA are hatched boxes. (A) A cassette exon can be either included in the mRNA or excluded. 
(B) Mutually exclusive exons occur when two or more adjacent cassette exons are spliced such 
that only one exon in the group is included at a time. (C, D) Alternative 5' and 3' splice sites allow 
the lengthening or shortening of a particular exon. (E, F) Alternative promoters and alternative 
poly(A) sites switch the 5'- or 3'-most exons of a transcript. (G) A retained intron can be excised 
from the pre-mRNA or can be retained in the translated mRNA. (H) A single pre-mRNA can 
exhibit multiple sites of alternative splicing using different patterns of inclusion. These are often 
used in a combinatorial manner to produce many different final mRNAs.  
 
(This picture is reproduced from Annual Review of Biochemistry 2003 72: 291-336) 
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Although there are very few examples in which the precise mechanisms of 
alternative splicing are known, the general scheme for alternative splicing is better 
characterized. Similar to constitutive pre-mRNA splicing, alternative splicing is mediated 
by the spliceosome. In addition, alternative splicing requires specific factors, such as the 
serine-arginine rich (SR) proteins and small nuclear ribonucleoprotein particles 
(snRNPs). They are essential for both the operation and regulation of the alternative 
splicing. These splicing factors selectively bind to the 5’ or 3’ splice sites, or to other pre-
mRNA sequences called exonic or intronic splicing enhancers (ESEs or ISEs) and 
silencers (ESSs or ISSs), and subsequently stimulate or repress exon recognition. The 
whole process involves the choice of competing splice sites. (Maniatis and Tasic, 2002; 
Shin and Manley, 2004). 
 
1.3.1 Alternative splicing and molecular diversity 
Alternative splicing has been proposed as one of the major means for generating 
molecular diversity. Based on genomic studies, about 40-60% of the human genes 
undergo alternative splicing (Modrek and Lee, 2002). By using different splice donor and 
acceptor sites, in theory one gene can produce hundreds to thousands of distinct proteins. 
Alternative splicing plays an important role in normal physiological functions, for 
example, the alternative splicing of Sxl and sequentially the expression of other genes to 
dsx gene determined the sex differentiation in D. melanogaster flies (Forch and 
Valcarcel, 2003). Furthermore, the alternative splicing of Dscam genes could produce 
more than 20,000 different exon-combinations and might underlie the molecular diversity 
Chapter I Introduction 
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in neuronal synapse formation (Schmucker et al., 2000). In the ion channel area, 
alternative splicing of Slo from chick cochlea generated kinetically distinct calcium-
activated potassium (BK) channels (Navaratnam et al., 1997; Ramanathan et al., 1999). 
The versatility of alternative splicing in genetic control is also demonstrated in examples 
of the choice of alternative splicing in response to physiological or pathological triggers. 
For example, stress hormone has been found to regulate the skipping of the STREX 
(stress axis-regulated) exon in the BK potassium channel to increase the repetitive firing 
of chromaffin cells (Xie and McCobb, 1998; Xie and Black, 2001). In the GH3 pituitary 
cells, depolarization activates a Ca2+/calmodulin dependent protein kinase (CaMK IV). 
The activated CaMK IV in turn phosphorylates unidentified repressor proteins that bind 
specifically to the CaMK IV-responsive RNA element (CaRRE) on the Slo pre-mRNA, 
which is located between the polypyrimidine tract and the 3’ splice site. The 3’ splice site 
of the STREX exon is therefore not used and which results in skipping of the STREX 
exon in the mature mRNA (Xie and Black, 2001; Shin and Manley, 2004).  
 
1.3.2 Alternative splicing and human diseases 
It has been reported that mutations located in noncoding regions, such as those 
affecting 5’ and 3’ splice sites, branch sites or polyadenylation signals, are frequently the 
cause of hereditary disease (Caceres and Kornblihtt, 2002). Approximately 15% of 
mutations that cause genetic disease affect pre-mRNA splicing (Krawczak et al., 1992). 
These mutations affect pre-mRNA splicing by including part of the intron or skipping a 
constitutive exon. The aberrantly spliced mRNA might have an interruption in the 
sequence or an abnormal sequence, and the protein it codes for may lose its original 
Chapter I Introduction 
 
 
                                                                                                                                                                       12 
 
function. As a result, this mutated protein with altered function may cause disease in 
patients. 
Many examples of misregulation of alternative splicing that lead to disease were 
reviewed recently (Grabowski and Black, 2001). Here are two notable examples: 
abnormal alternative splicing in the microtubule binding protein tau which leads to 
increased inclusion of alternative exon 10 is believed to generate the phenotypes of the 
inherited disorder, FTDP-17. Characteristic features of FTDP-17 pathology include 
filamentous tau aggregates in neuronal or glial cells of brain (D'Souza et al., 1999; 
Hutton, 2001). Lin et al reported that misregulation of alternative splicing in the 
glutamate transporter EAAT2 causes part of intron retention and exon skipping, and the 
resultant phenotype is amyotrophic lateral sclerosis and neuromuscular disease (Lin et al., 
1998; Meyer et al., 1999).  
 
1.3.3 Alternative splicing and Voltage-gated calcium channels 
Alternative splicing has been demonstrated in many types of VGCCs. In neuronal 
VGCCs, alternative splicing of pore-forming α1-subunits has been extensively studied in 
P/Q type calcium channel Cav2.1 (Bourinet et al., 1999; Soong et al., 2002), in N-type 
calcium channel Cav2.2 (Lin et al., 1997; Stea et al., 1999; Bell et al., 2004), and in other 
L-type calcium channels such as Cav1.3 (Safa et al., 2001) and Cav1.4 (McRory et al., 
2004). Alternative splicing of T-type calcium channel has been reported by Mittman et al 
(Mittman et al., 1999a; Mittman et al., 1999b; Murbartian et al., 2002). With regards to 
the auxiliary subunits, alternative splicing of β2 subunit of Cav1.2 channel generates 
distinctive modulatory effects on L-type calcium channel gating (Yamada et al., 2001; 
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Takahashi et al., 2003); and splice variants of α2 subunits were also identified in rat 
brains (Kim et al., 1992). Generally, studies on alternative splicing in these calcium 
channel pore-forming α1 subunits and auxiliary subunits, have demonstrated that 
alternative splicing generates the altered channel phenotypic variations. 
 
1.3.4 Alternative splicing of Cav1.2 α1 subunit 
The investigations of alternative splicing of Cav1.2 α1 subunit (α11.2) have been 
carried out in many different species including rabbit, rat, mouse and human being 
(Mikami et al., 1989; Biel et al., 1990; Koch et al., 1990; Perez-Reyes et al., 1990; Snutch 
et al., 1991; Soldatov, 1992; Schultz et al., 1993; Soldatov, 1994; Shistik et al., 1998; 
Bielefeldt, 1999; Dai et al., 2002; Pang et al., 2003). These studies shed light on our 
understanding of the alternative splicing in α11.2. Based on these studies, we know that 
12 exons that can undergo alternative splicing out of a total of 53 known exons. These 
exons are the mutually exclusive exons 1/1a, 8/8a, 21/22, 31/32; and the alternative exons 
like exon 9* (found in rabbit and rat), exon 33, exon 45a and exon 45. 
 Electrophysiological studies have been carried out to test the functional impact of 
the inclusion or exclusion of the alternatively spliced exons. It was reported that exon 1a 
has an inhibitory effect on channel gating and this inhibitory effect is attenuated by 
protein kinase C, although the exact phosphorylation sites are still unknown (Shistik et 
al., 1999). Exon 45a was shown to play a role in oxygen sensing (Fearon et al., 2000).   
In a pathological study, Gidh-Jain M et al reported there is a significant increase 
in mRNA level of the fetal isoform (exon 31) in noninfarcted myocardium in adult rats 
during left ventricular remodeling (Gidh-Jain et al., 1995). Yang et al reported there was 
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the exon switching of the mutually exclusive exon 31/32 (Yang et al., 2000). This group 
found that in normal hearts there were a higher inclusion of exon 31, but in the hearts 
from heart failure patients, there was twice the amount of exon 32 as exon 31 expressed 
in the α11.2 channel. Recently, a de novo point mutation within mutually exclusive exon 
8a was identified in a disorder, Timothy’s syndrome (Splawski et al., 2004). Multiple 
organ systems were affected, including heart, skin, eyes, teeth, immune system and brain. 
Interestingly, this de novo point mutation occurs only in exon 8a, but not in the mutually 
exclusive exon 8; this exon encodes the IS6 transmembrane segment (Fig. 1.2). 
Electrophysiological characterization of the G406R mutant Cav1.2 channel showed an 
almost complete loss of voltage-dependent inactivation, and the large current density was 
suggested to account for severe arrhythmias, congenital heart disease, cognitive 
impairments and autism. 
These previous studies have reported generally on the impact of alternative 
splicing on Cav1.2 channel functions by characterizing limited numbers of cDNA clones 
isolated from a single library, and no comprehensive or systematic scan of α11.2 splice 
variation has been performed, particularly in the human brain and heart. Furthermore, the 
knowledge of 12 known alternatively spliced exons poses an intriguing question: what 
are the exon-combinations (i.e. exon-combinations of alternatively spliced exons of α11.2 
subunit) or splicing profiles in full-length α11.2 transcripts in human beings and other 
species? Presently, such information is unavailable, leaving a critical gap in knowledge in 
the Cav1.2 channel field. 
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1.4 Hypertension 
Hypertension is one of the most common chronic diseases, and is the leading risk 
factor for deaths due to stroke, myocardial infarction or end-stage renal failure (Kannel, 
2000). In primary hypertension, the causes of the disease remain enigmatic and multiple 
etiologies may interact to produce the higher blood pressure in patients. The World 
Health Organization has defined hypertension as a systolic pressure greater than 140 
mmHg, a diastolic pressure greater than 90 mmHg, or both. Generally, lowering blood 
pressure is the primary goal in treatment for this kind of hypertension. Clinical trials have 
clearly demonstrated that lowering blood pressure markedly reduces the incidence of 
primary stroke (Chalmers, 1998). In addition to the agents like angiotensin-converting 
enzyme (ACE) inhibitors, angiotensin receptor antagonists, antiadrenergic drugs, 
diuretics and vasodilators, calcium channel blockers (mainly DHPs) are one of the 
effective agents currently in use to reduce high blood pressure (Williams, 2001). 
 
1.4.1 Hypertension and Cav1.2 channel blockers 
As mentioned previously, Cav1.2 channels play an important role in controlling 
the contraction of smooth muscle cells, and the channel blockade by DHPs has a 
beneficial effect on lowering the blood pressure. However, previous studies have shown 
α11.2 subunits are subjected to extensive alternative splicing (Soldatov, 1992, 1994; 
Klockner et al., 1997; Tang et al., 2004), and splice variants of α11.2 may change the 
pharmacological properties of calcium channel blockers. Welling et al. and Zuhlke et al. 
showed alternative splicing of exon 8a/8 and exon 21/22 affects sensitivity of DHPs 
toward the Cav1.2 channel (Welling et al., 1997; Zuhlke et al., 1998). Therefore, it will be 
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interesting to explore whether alternative splicing of the α11.2 subunit may be affected 
under pathological conditions such as in hypertension. If pathological triggers alter splice 
variations of the α11.2 subunit, then it leads to the further question of whether the altered 
splicing patterns of the α11.2 subunit may affect the physiological or pharmacological 
properties of Cav1.2 channel in hypertensive rats and humans. As there is no information 
about the alternative splicing of α11.2 under hypertensive conditions we investigated the 
alternative splicing of α11.2 subunit in rat hypertension models. In this study, 
Spontaneously Hypertensive Rats (SHR) have been used. The justifications for selection 
of this model are discussed in the following paragraphs. 
  
1.4.2 Spontaneously Hypertensive Rats and Alternative splicing 
The most common human form of hypertension, primary hypertension, is often 
represented by genetic models of hypertension, such as SHR (Pinto et al., 1998). SHR 
have been an established hypertension animal model for almost four decades. In this rat 
strain, the degree of genetic determination of blood pressure is 50-60%, and the 
environmental factors also play an important role. Even though the exact molecular 
mechanism underlying their hypertensive phenotype remains obscure, the hypertensive 
mechanisms in SHR are speculated to consist of both neurogenic and non-neurogenic 
factors, which contribute to the initiation and maintenance of hypertension. It is 
speculated that an abnormality of central mechanisms of blood pressure regulation results 
in increased sympathetic outflow and elevated blood pressure (Chalmers, 1998). Both the 
elevation of blood pressure itself and the increased sympathetic tone accelerate vascular 
protein synthesis which leads structural vascular changes are considered to be the final 
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common pathway, whatever the initiation mechanism of hypertension may be (Yamori, 
1994). Generally, the same origin strain Wistar Kyoto Rats are used as normotensive 
controls.  
Several studies have been carried out to understand the role of alternative splicing 
of the dopamine receptor and SERCA (sarco/endoplasmic reticulum Ca2+ ATPases) and 
PMCA (plasma membrane Ca2+ ATPases) genes in SHR (Autelitano and van den Buuse, 
1995; Martin et al., 2000; Martin et al., 2002). These studies have reported that some 
genes are subjected to either exon-switching or alteration in the expression level of the 
transcript under hypertensive conditions. Nonetheless, even though previous studies have 
shown that alternative splicing of α11.2 subunits is altered in other pathological 
conditions such as myocardial infarction and heart failure (Gidh-Jain et al., 1995; Yang et 
al., 2000), there is no data concerning about the alternative splicing of α11.2 under 
hypertensive conditions. These gaps of knowledge provide another rationale to carry out 
a comparative study on alternative splicing of α11.2 subunits in SHR and normotensive 
WKY rats.  
Hence one of the aims in this study was to investigate whether there are exon-
switching or alteration of expression level of α11.2 subunit in the smooth muscle of blood 
vessel and cardiac muscle in the SHR vs. WKY rats. 
1.5 Objectives of the Study 
The objectives of this research were to systematically search for the entire suites 
of alternatively spliced exons of the α11.2 subunit and to determine the combinatorial 
splicing profiles of the α11.2 subunit in physiological and pathological conditions. To 
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achieve these aims, the experimental approaches were constructed as follows: (1) A 
transcript-scanning method was applied to search for new splice variants of α11.2 gene, 
CACNA1C, in four human cDNA libraries: adult and fetal brain, and adult and fetal 
heart; (2) Nested-PCR was used to determine the distribution of alternatively spliced 
forms of CACNA1C in human heart and brain; (3) Whole cell patch clamp recording was 
applied to characterize the electrophysiological properties of the CACNA1C splice 
variants; (4) A reverse transcriptase PCR (RT-PCR) method was recruited to investigate 
possible exon-switching and altered expression level of Cacna1c in hypertensive 
conditions using the Spontaneously Hypertensive Rat model; and (5) a full-length PCR 
combining with exon-specific colony PCR method to analyze the exon-combination of 
alternatively spliced exons of α11.2 cDNA in rat heart and aortic tissues. 
1.6 Significance of the Study  
This study would provide comprehensive information and new knowledge about 
the extent and complexity of splice variations of α11.2 subunit in human heart and brain. 
Firstly, the new splice variants and tissue-specific alternative splicing patterns of 
α11.2 subunit found in this study should enrich our understanding of the molecular 
diversity of Cav1.2 channels that are important in maintaining normal physiological 
functions. The altered electrophysiological properties of the α11.2 splice variants found in 
this study would lend support to the concept that alternative splicing is an important 
mechanism in generating functional Cav1.2 channel diversities. Secondly, the exon-
switching found in the hypertensive rat model SHR vs. WKY rats would shed light on the 
mechanistic regulation of alternative splicing of α11.2 subunit in response to hypertensive 
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triggers. Thirdly, the identification of exon-combinations in full-length cDNAs of heart 
and aortic tissues would provide the essential molecular evidence to our understanding of 
functional difference of Cav1.2 channels in both tissues. Finally, in addition to our better 
understanding of the pharmacological mechanism of DHPs in cardiovascular disease, the 
distinct splice patterns of α11.2 subunit in the heart and aortic tissues revealed by this 
study would provide potential novel drug targets for future drug screening of Cav1.2 
channel antagonists or agonists. This in turn may help to improve the efficacy and to 
reduce the side-effects of drugs acting on Cav1.2 channels.  
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Part I. Study for alternative splicing in 
human α11.2 gene  
 
2.1 Transcript-scanning by PCR and sequencing  
The transcript-scanning method has been applied by Mittman et al (Mittman et al., 
1999a; Mittman et al., 1999b) and by Soong et al (Soong et al., 2002) to systematically 
search for alternatively spliced exons of the CACNA1I, CACNA1G and CACNA1A 
genes. Here, the method is briefly described as follows. PCR was carried out to acquire 
overlapping amplicons covering all exon-exon junctions of the CACNA1C gene by 
amplifying 4 human cDNA libraries (CLONETECH). They included human adult whole 
brain cDNA libraries (Quick-clone , Lot# 1110198 and Marathon cDNA, Lot# 
2090119); human fetal brain cDNA libraries (Quick-clone , Lot# 1011233 and 
Marathon, Lot# 2070616);  human adult heart cDNA libraries (Quick-clone , Lot# 
0080201 and Marathon, Lot# 1080911); and human fetal heart cDNA libraries (Quick-
clone , Lot# 2060045 and 8110445). PCR primers designed by using the Oligo 6.1 
program (Molecular Biology Insights, Cascade, CO) are shown in Table 2.1. All PCR 
amplicons were cloned into pGEM-T Easy (Promega™) or TOPO 2.1 (Invitrogen) 
Vector and transformed into DH10B E. coli cells. Eight to thirty two colonies from the 
transformation were screened for splice variations by colony PCR. All PCR products 
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were analyzed by electrophoresis in 1-5% agarose gel and the products with different 
migration rates were further subjected to DNA sequencing analysis. For PCR products 
with identical migration rates, 2-4 of them were also sent for DNA sequencing. The 
sequencing results were compared against the National Center for Biotechnology 
Information (NCBI) public databases by using BLASTN program. DNA sequence 
alignments to detect splicing of exons or alternate use of junctional sites were performed 
using the Lasergene Software (DNA Star, Madison, WI). See Fig. 3.1 for the strategy for 
the transcript-scanning of the CACNA1C gene. 
  For all PCR reactions, PCR conditions were varied according to the different 
annealing temperatures for the primer pairs used (Table 2.1). Briefly, the PCR cycles 
were as follows: denaturation at 94oC (5 mins), 5 cycles of touch-down protocol 
involving denaturation at 94oC (30 sec), annealing temperature decreased by 1oC per 
cycle from 57oC to 53oC for 30 sec, and extension at 72oC (1 min). The annealing 
temperature for the final 30 cycles was 52oC (30 sec). The PCR ended with an extension 
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  Table 2.1 PCR Primers for transcript-scanning of human α11.2 subunit 







1 Primer A 5’- GATACGATACGGCCATGT -3’ 1a-2 550 49 
2 Primer B 5’- CCATTCGACAATGCTGAT -3’    
3 1C-184U18 5’- CCACGGCTTCCTCGAATC -3’ 1-2 568 57.8 
4 1C-731L21 5’- GGGAATATAGATCGCTAAGGC -3’    
5 1C-553U21 5’- GCGGAAGCGGCAGCAATATGG -3’ 3-4 448 59.1 
6 1C-980L21 5’- GGCCCCTTTCCCTCCGAGAGC -3’    
7 1C-889U21 5’- CAACGGCTGGAACCTACTAGA -3’ 5-6 480 58 
8 1C-1349L20 5’- GCGAAGGCAAAGTTGTCAAA -3’    
9 1C-1208U21 5’- TACAACCAGGAGGGCATAGCA -3’ 7-8 439 57.6 
10 1C-1629L18 5’- CGGCCTGAGTGATCCAAT -3’    
11 1C-1452U16 5’- GGCCCTGGATCTATTT -3’ 9-11 489 54.5 
12 1C-1920L21 5’- AGGCAATGGTGAGCGTGTTGA -3’    
13 1C-1711U21 5’- GCCCACCAGTGAGACCGAGTC -3’ 11-13 569 59.7 
14 1C-2263L17 5’- GGAGCAGGGAGGCGATG -3’    
15 1C-2084U21 5’- TTTGACTGCTTCGTCGTGTGT -3’ 14-16 670 56.4 
16 1C:2738L16 5’- CTCCGTCAGCCGTGAT -3’    
17 1C:2485U21 5’- TCCAGGGATGTTAGTCTGTAT -3’ 16-20 664 54.8 
18 1C:3130L19 5’- GGTGAAAATGGTGGTAAAA -3’    
19 1C:2992U21 5’- CCACCGCATTGTCAATGACAC -3’ 21-24 481 56.6 
20 1C:3454L19 5’- CACGATGTTCCCGATGGTC -3’    
21 1C:3261U19 5’- CTTTCTGCCGGAACTACTT -3’ 24-27 611 56 
22 1C:3851L21 5’- GATGACGAAGCCCACGAAGAT -3’    
23 1C:3692U16 5’- GCCCTCTTCACCGTCT -3’ 28-30 568 55.6 
24 1C:4239L21 5’- TTATGCTGCCAATTACGATGA -3’    
25 1C:4102U21 5’- GAGCTGCCTGTTCAAAATCGC -3’ 30-35 500 57.1 
26 1C:4583L19 5’- ACACCTGCATCCCGATCAC -3’    
27 1C:4450U16 5’- CCGGGTCATGCGTCTG -3’ 35-37 482 58.5 
28 1C:4911L21 5’- GGGGACCAAGGATGGACCAGT -3’    
29 1C:4786U21 5’- TGAAACACCCTGTGGTAGCAG -3’ 38-39 362 56.9 
30 1C:5129L19 5’- CAAACAGGGTGGCATTGAA -3’    
31 1C:4952U21 5’- CAGGAACGTGGCGTAGAACTT -3’ 39-41 371 55.5 
32 1C:5306L21 5’- AGAATCTGGGCAGAGTATGAC -3’    
33 1C:5103U21 5’- CTCTGAACAGCGACGGGACAG -3’ 41-43 644 60.2 
34 1C:5729L18 5’- GGAGCCGGTGGACGAGTA -3’    
35 1C:5511U18 5’- AGGCTGTGTCCGCTGCTT -3’ 44-45 594 61 
36 1C:6084L21 5’- AGGCCTCCGTGTCATGGTTCA -3’    
37 1C:5809U17 5’- CCCGATGATGGCGTAGATGA -3’ 45-47 485 61.1 
38 1C:6273L21 5’- CTCGGTCCTTCTGTCGCTTCA -3’    
39 1C:6187U21 5’- CAAGAGGGACATCCGGCAATC -3’ 48-49 615 62.2 
40 1C:6785L17 5’- TTGTCGGCCGCGCTCTC -3’    
41 1C:6472U16 5’- CACCCTGCGGCTTGAG -3’ 50 608 60.5 
42 1C:7059L21 5’- CCGGTTAACTCCAGGTCACGA -3’    
 
Table 2.1. List of PCR primers for transcript-scanning of human α11.2 subunit. 
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2.2 PCR for exon 1a 
 
  Exon 1a specific primers (primers No. 1 and 2, Table 2.1) were employed for 
PCR from human adult heart, fetal heart, adult brain and fetal brain cDNA libraries. 
(Quick-clone  and Marathon cDNA, CLONETECH). PCR was performed under the 
following conditions: First cycle, denaturation at 950C for 3 minutes followed by the next 
5 cycles of touch-down protocol, denaturation at 940C for 30 sec, annealing temperature 
progressively decreased from 570C to 530C for 30 sec, and extension at 720C for 1 min. 
The other 30 cycles maintained the annealing temperature at 520C. The final elongation 
was performed at 720C for 5 min. 
 
2.3 Reverse Transcriptase PCR from human aortic smooth muscle cells  
 
 Total mRNA was extracted from T/G HA-VSMC line (ATCC, from the normal 
aorta of 11-month-old child) after growing to confluence in 75cm2 flask in Kaighn’s 
modification of Ham’s F12 medium with 2 mM L-glutamine (supplied by the ATCC). 
RT-PCR was carried out using CACNA1C specific first strand primer 
(GTTGGGCTGGTTGTAGTGCTC) and PCR primers (upper primer 
AAGATGCACAAGACCTGCTAC, lower primer CACCTCCAGCCACGTT) covering 
the region exon 6 to 10, and the products were separated in a 2% agarose gel. 
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2.4 Distribution study of splice variations in IVS3-IVS4 region in 
α11.2 subunit 
  Nested PCR was used in examining the distribution of splice variants in the IVS3-
IVS4 region. First PCR amplification across regions between either exons 28 to 37 
(Primer No.21 and 26, Table 2.1) or exons 30 to 34 (Primer No. 23 and 24, Table 2.1) 
was performed using human adult whole brain, fetal brain, adult heart and fetal heart 
cDNA libraries (Quick-clone  and Marathon cDNA, CLONETECH). The amplicons 
were cloned into pGEM-T Easy (Promega) Vector and transformed into DH10B E. coli 
cells. About 300 bacterial colonies from each group were picked as templates in second 
PCR screening using either exon 31 specific forward primer: (5’-
CAGCATAATTGACGTCATTC-3’) or exon 32 specific forward primers: (5’-
TGTTGATATAGCAATCACC-3’), with the same reverse primer :(5’-
CTTCACCAGACGCATGAC-3’).   PCR fragments containing either one of six exon-
combinations, i.e., +31+32+33, +31-32+33, -31+32+33, -31+32-33, -31+32-6nt+33 and  
-31+32-6nt-33 subcloned into pGEM-T Easy (Promega) Vector were used as controls to 
determine the distribution of the putative mutually exclusive exons 31/32 (Perez-Reyes et 
al., 1990; Snutch et al., 1991; Diebold et al., 1992) and the combinatorial coordination of 
exon 32 with 6 nucleotides and exon 33 in the above-mentioned four cDNA libraries. The 
different exon-combinations were differentiated based on their distinct migration rates in 
5% agarose gel. To verify the accuracy of this analysis, 80 sample plasmids were 
extracted from representative colonies and sent for DNA sequencing to validate the 
results by colony PCR screening. 
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2.5 Construction of full length α11.2 splice variants into pcDNA3 vector 
  The parental full length CACNA1C (α1C77WT) in pBluescript vector (Zuhlke et 
al., 1999) was kindly provided by Dr R.D. Zuhlke (Swiss Agency for Therapeutic 
Products, Switzerland). It contains the combination of exons of 1-20, 22-30, 32-44, and 
46-50. PCR fragments containing variation A (-31+32-6nt-33),  variation B (–31+32-
6nt+33), variation C (-31+32-33) were amplified from adult heart cDNA libraries using 
primers No.23 and No.28 (Table 2.1), and variation D (+31-32+33) were amplified from 
fetal heart cDNA libraries using the same primers. The 4 splice variations were 
substituted into α1C77WT (-31, +32, +33) in pBluescript using restriction enzymes BclI 
and BstBI. The various full-length human α11.2 containing splice combinations of the 
IVS3-IVS4 region were sub-cloned into pcDNA3 expression vector using restriction 
enzymes HindIII and XbaI (Fig. 2.2). The human α11.2 splice variant clones were named 
α1C77-A (-31, +32-6nt, -33), B (–31, +32-6nt, +33), C (-31, +32, -33) and D (+31, -32, 
+33). The identities of all the constructs were confirmed by DNA sequencing.  
2.6 Transient expression of human α11.2 splice variants in HEK293 cells 
Approximately 1:1:1 molar ratios of cDNA for the α1 subunit of Cav1.2 and its 
variants, β2a and α2bδ were applied for transfection of HEK 293 cells.  In the 35 mm petri 
dish, 1.65µg of cDNA of α1 subunit of Cav1.2 (α1C77WT or its variants) together with 
1.25 µg of β2a, 1.25µg of α2bδ, and 0.2 µg of TAG ( T antigen) were transiently co-
transfected into HEK293 cells (Human Embryonic Kidney 293 cells) using a calcium-
phosphate mediated method (Peterson et al., 1999). Transfected HEK293 cells were 
grown for 36-48 hours in 5% CO2 incubator at 370C before patch clamp analysis. 
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2.7 Whole-cell patch-clamp electrophysiology  
Whole-cell patch clamp technique (pClamp8.1, Axon Instruments) was employed 
to study the electrophysiology of the transiently expressed splice variants. The bath 
solution contained (in mM): TEAMS, 140; HEPES, 10; BaCl2, 5. pH=7.3, 300 mOsm, 
adjusted with glucose. Internal solution contained (in mM): Cs-MeSO3, 138; CsCl2, 5; 
EGTA, 0.5; MgCl2 ,1; MgATP, 4 and HEPES, 10. pH=7.3, 290 mOsm, adjusted with 
glucose. Reported voltages are uncorrected for a -11mV junction potential, and true 
voltage may be obtained by subtracting 11 mV from reported values. Whole-cell currents, 
obtained under voltage clamp with an Axopatch 200A amplifier (Axon Instruments), 
were filtered at 2 kHz and sampled at 10 kHz. Series resistance was typically 1-2 MΩ 
after > 70% compensation. Leak and capacitive transients were subtracted by a p/4 
protocol.  
 Current-voltage relationship recording (I-V curve recording): Holding voltage 
was -90 mV and test pulses were a variable-voltage family from -50 to +50 mV for 1s, 
and the depolarizations were delivered every 60s. 
 Steady-state activation protocol (traditional tail current recording):  After being 
held on -100 mV for 10 ms, channels were applied a variable-voltage family from -40 to 
120 mV for 20 ms, and tail currents were measured after repolarization to -50 mV. 
Repeated interval was 30s.   
 Steady-state inactivation protocol: Using a three-pulse protocol in which a 10-ms 
prepulse to 0 mV was followed in turn by a family of 15-s conditioning pulses (-120 to 
+20 mV), and a 100-ms test pulse to 0 mV. Repeated interval was 105s. 
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2.8 Data analysis of electrophysiological recording 
 Data were analyzed using Microsoft Excel and Graphpad Prism IV software, and 
were displayed as mean values ± SE. Current-voltage relationship, steady-state activation 
and steady-state inactivation profiles were well-described by the following equation, with 
parameters determined using least-squares criteria. 
 I-V curves were fitted by IBa= Gmax(V-Erev)/[1+exp(V-V1/2)/kI-V], where 
Gmax=maximum conductance, Erev=reversal potential, V1/2=voltage at 50% of IBa 
activation, and kI-V=slope factor. n= number of tested cells (Soldatov et al., 1997; Zuhlke 
and Reuter, 1998). 
 Steady-state activation data were fitted by a dual-Boltzmann function of the form:  
G/Gmax = Flow/[1 + exp[(V1/2,low –V)/klow]+ (1-Flow)/[1 +exp[(V1/2,high –V)/khigh], where G 
is the tail current, Gmax is the tail current evoked by a depolarization to +120 mV, Flow is 
the fraction of the low threshold component, V is the membrane potential of the test 
pulse, V1/2,low, V1/2,high , klow, and khigh are the half-activation potentials and slope factors 
for the low- and high-threshold components, respectively (Takahashi et al., 2003). 
 Steady-state inactivation data were fitted by a Boltzmann function of the form: 
 h(15s)= I2/I1 = (A1-A2)/[1+exp[(V-V1/2)/k]+A2, where I2 is the test-pulse current, I1 is the 
normalization current, A1 is initial current amplitude, A2 is final current amplitude, V is 
the membrane potential of the conditioning pulse, V1/2 is the potential for half-
inactivation, and k is the slope factor (Lacinova et al., 2000). 
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Part II. Analysis of alternative splicing in the 
rat α11.2 gene 
 
2.9 Measurement of blood pressure of SHR and WKY rats 
 The blood pressures of five SHR and WKY rats were measured to confirm that 
the high blood pressure was fully developed in SHR before the hearts and aortas were 
collected. The blood pressure was measured using a non-invasive intermittent blood 
pressure measurement, i.e., the tail-cuff method (ML125 system, Powerlab, 
ADInstruments). In both SHR and WKY groups, 3 male and 2 female from each group 
were examined. WKY rats and SHR were purchased from the Animal Resources Center 
(Canning Vale, WA 6970, Australia) and were 14-18 weeks old before they were 
sacrificed. The animals were euthanized by CO2 and then heart and aortic tissues were 
quickly collected and stored in RNAlater reagent. For detecting hypertrophy in the hearts 
of SHR and WKY animals, the whole animals, hearts and ventricles from three SHR and 
WKY were weighed and heart weight/body weight, ventricle weight/body weight were 
calculated. 
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2.10 mRNA extraction and reverse transcription for first strand cDNA 
of rat α11.2 gene 
 Total RNA was extracted from ventricular and aortic tissues of 5 SHR and WKY 
rats by RNeasy® Kits (QIAGEN Science, Maryland, USA).  Reverse transcription was 
separately carried out with SUPERSCRIPT II (Invitrogen, CA, USA). RT-PCR for 
individual rat RNA samples was performed separately. The primer for first strand cDNA 
was rat Cacna1c specific (primer No. 69, Table 2.2). Negative control (reaction with 
RNA but without reverse transcriptase, RT) was carried out in all reactions to rule out 
contamination.  
2.11 Exon specific PCR for determining the distribution of exon 1a and 
exon 1 
 The differential distribution of exon 1a and exon 1 in human tissues observed in 
our results led us to test whether the same observation could be detected in rat. Heart 
cDNA from 4 SHR and aorta cDNA from 3 SHR were used to assess the specific 
expression of exon 1a and exon 1 by exon-specific PCR (primer No. 43, 44 and No. 45, 
46, respectively, Table 2.2). Positive controls were performed on the rbC-II cDNA 
plasmid (Snutch et al., 1991). Negative controls were done by using H2O instead of 
template cDNA for PCR reactions. PCR conditions were: denature at 94 0C for 30 
seconds, annealing at 52 0C for 30 second, and then extension at 72 0C for 1.5 minute. A 
total of 40 cycles were performed.  
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Table 2.2 Primers for rat Cav1.2 α1 subunit study 
 
 
2.12 Full-length RT- PCR for α11.2 subunit cDNA from SHR and WKY 
rats 
 Before the full-length PCR reactions were performed, first strand cDNA was 
stringently examined to rule out contamination using 2 different short fragment PCR 
reactions. These PCR reactions covered exon 6-12 (primers No. 55 and 56, Table 2.2) 
and exon 44-47 (primers No. 67 and 68, Table 2.2) regions respectively and were 
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performed together with the negative controls to rule out possible DNA contamination. In 
the negative controls, PCR reactions used H2O and mRNA without the treatment of 
reverse transcriptase as templates. 
 Exon 1a was found to be expressed specifically in heart, while exon 1 was 
expressed in both heart and aorta (Fig. 3.7 and Fig. 4.1). As such, full-length PCR 
reactions were carried out to amplify the full-length Cacna1c transcripts from exon 1a to 
exon 50 (exon 1a-50) and from exon 1 to exon 50 (exon 1-50) in rat ventricular cDNA, 
but only exon 1-50 full-length PCR products were generated from rat aorta cDNA. To 
rule out PCR contamination, the same negative controls as previously described were 
adopted. Five PCR products from 5 individual SHR or WKY rats with similar band 
intensities were pooled together to generate full-length cDNA libraries of Cacna1c. The 
reason for pooling the samples was due to the small number of colonies generated in 
individual full-length PCR products and low success rate (15-30%) for producing 
plasmids containing full-length α11.2 clone. Based on the different rat strains, different 
tissues and different first exon (exon 1a or exon 1), six cDNA libraries were generated. 
They were named as WKY heart exon 1a-50, SHR heart exon 1a-50, WKY heart exon 1-
50, SHR heart exon 1-50, WKY aorta exon 1-50 and SHR aorta exon 1-50 cDNA 
libraries. These 6 cDNA libraries were cloned into PCR-XL vectors (Invitrogen) and 
further transformed into DH10B Escherichia coli competent cells. The averaged success 
rate for transforming the full-length in PCR-XL into DH10B cells was about 20% in this 
study. After screening around 4000 colonies by colony PCR methods (exon 6-12, primers 
No. 55 and 56; exon 44-47, primers No. 67 and 68, Table 2.2), a total of 689 colonies 
representing 6 full-length cDNA library were picked into 96-well cell culture plates. Each 
Chapter II Materials and Methods 
 
 
                                                                                                                                                                       33 
 
colony library had around 92-116 clones, except for the colony library for SHR aorta 1-
50 that comprised 189 clones. These colony libraries are designated as SHR heart 1a-50, 
SHR heart 1-50, SHR aorta 1-50, WKY heart 1a-50, WKY heart 1-50 and WKY aorta 1-
50, respectively. 
 
2.13 Exon specific PCR for identifying exon-combinations in the 
α11.2 subunit in rat full length cDNA libraries 
 For each full-length cDNA library, seven PCR reactions were carried out to 
identify its exon-combinations. Six were exon specific PCR reactions and their primers 
were listed in Table 2.2: exon 8a-12 (primers No. 51 and 52), exon 8-12 (primers No. 53 
and 54), exon 17-21 (primers No.57 and 58), exon 17-22 (primers No.59-60), exon 31-35 
(primers No.63-64) and exon 32-35 (primers No. 65-66). The last reaction was to identify 
the alternative splicing in C-terminus region spanning exon 44-47 (primers No. 67-68), 
where there are alternative exon 45 * and exon 45 reported elsewhere (Klockner et al., 
1997).The forward primer for exon 32 specific PCR was designed to end at the last 
nucleotide of exon 32. Hence, it would not bind to the splice variation exon 32-6nt, in 
which last 6 nucleotides of exon 32 were spliced out, when the annealing temperature at 
570C was used for colony PCR screen. Specificity was confirmed in 12 clones from SHR 
heart 1a-50 and in 6 clones from WKY heart 1a-50. These clones showed negative results 
in either exon 31 or exon 32 specific PCR, but sequencing results proved they were 
deleted in the last 6 nucleotides in exon 32. Untransformed colonies were used as 
negative controls and colonies containing full-length rat α11.2 gene with the respective 
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mutually exclusive exon were applied as the positive controls. At least 5 clones from 
each PCR experiment were sent for sequencing to verify the exon specific PCR results.  
 Generally, colony PCR conditions were: denaturation at 94oC (5 mins), 5 cycles 
of touch-down protocol involving denaturation at 94oC (30 sec), annealing temperature 
decreased by 1oC per cycle from 61oC to 57oC for 30 sec, and extension at 72oC (1 min). 
The annealing temperature for the final 30 cycles was 57oC (30 sec). The PCR ended 
with an extension step performed at 72oC for 5 min. 
2.14 Data analysis for full-length exon-combinations in rat 
α11.2 transcripts from SHR and WKY rats 
 The ratios of individual alternatively spliced exons, exon-combinations and their 
standard deviation were calculated. A two-sided z-test was applied to compare the 
statistical significance between the proportions of individual alternatively spliced exons 
and exon-combinations from SHR and WKY rats. Normally, for fulfilling the conditions 
of z-test, only ratios obtained from clone number greater than or equal to 5 were 
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3.1 The transcript-scanning method for human α11.2 gene    
 A diagrammatic representation of the α11.2 subunit of human Cav1.2 channel is 
shown in Fig. 3.1A. The α11.2 subunit consists of four domains comprising 24 
transmembrane segments (vertical barrels) connected by intervening cytoplasmic loops 
represented as horizontal bars. Multiple original PCR reactions were carried out to cover 
all 53 exons of α11.2 subunit transcript (Fig. 3.1B). PCR amplifications cover 1-5 exons 
and the sizes of products are 360 to 670 bp. Following the original PCR reactions, the 
second PCR reactions were performed in which the colonies containing original PCR 
fragments were used as templates. Generally, the second PCR would differentiate the 
splice variations based on their different migration rates. Analyses by DNA sequencing 
of the PCR products and examination of all exon-exon junctions would reveal all possible 
splicing loci of the human α11.2 subunit in a given tissue. Fig. 3.1C is an example in 
which amplicon 30-35 was sub-cloned into the pGEM-T Easy vectors and screened by 
colony PCR. Four splice variations at the IVS3-S4 region were demonstrated when 
analysed by electrophoresis in a 5% agarose gel. 
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Fig. 3.1 Schematic representation of human L-type voltage-gated calcium channel, α11.2 subunit 
and transcript-scanning PCR reactions used to detect splice variations. A. Diagram of the α11.2 
subunit structure showing four domains (I-IV), each consisting of 6 transmembrane segments (1-
6). B. Locations of the 20 overlapping PCR amplicons covering the entire cDNA. The last 
amplicon was for detecting splicing of exon 50. Traditionally, the exons were named numerically 
1-50 and together with 3 exons named 1a, 8a and 45* makes a total of 53 known exons. C. 
Scanning of exon 30-35 uncovered splice variations revealed by different PCR product size. 
 
3.2 Novel and extensive splice variations revealed by transcript scanning 
 Figure 3.2 shows the result of the systematic search of splice variations of the 
CACNA1C gene in human whole brain, fetal brain, adult heart and fetal heart cDNA 
libraries. In total, 19 exons were found to be subjected to alternative splicing. Four pairs 
of exons were by and large spliced in a mutually exclusive manner: 1/1a, 8/8a, 21/22 and 
31/32. Six exons including 9, 9*, 10*, 33, 45 and 45* were alternatively spliced while 7 
other exons were spliced at the alternate junctions namely 3, 7, 15, 17, 32, 41 and 45*. 
Exons 32 and 45* were unique as they could be spliced either as alternate exons or at 
alternate donor sites. Interestingly, as many as 12 splicing combinations were found in 
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IVS3-S4 region alone which are generated by the inclusion or exclusion of exons 32, 32-
6nt and 33 (6 combinations), exons 31 and 33 (4 combinations) and combinations of 
either (+31, +32, +33) or (+31, +32-6nt, +33). We found all the IVS3-S4 splice variations 
by screening human fetal and adult heart and brain cDNA libraries. Their detailed 
splicing patterns are illustrated in Fig. 3.3A and Fig. 3.3B. 
 
 
Fig. 3.2 Diagrammatic representation of exons of the human α11.2 subunit and the loci of various 
splice variations are indicated. There are 19 exons subjected to splicing: 6 are alternate exons 
indicated by black boxes (9, 9*, 10*, 33, 45 and 45*); 8 are mutually exclusive exons indicated 
by hatched boxes (1, 1a, 8, 8a, 21, 22, 31 and 32); and 7 exons are spliced at the junctions 
indicated by open boxes (3, 7, 15, 17, 32, 41 and 45*). Exons 32 and 45* can be spliced out 
entirely as an exon or at the donor site. Two exons - 9* and 10* - are novel exons as described in 
this report; the total number of exons in α11.2 subunit is now 55. 
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Fig. 3.3A and Fig. 3.3B. Loci of splice variations of α11.2 subunit distributed in human heart and 
brain.  Fig. 3.3A lists loci 1-8 while in Fig. 3.3B, loci 9-12 are illustrated. In particular, locus 10 
shows extensive splice variations. All 12 possible combinations of alternative splicing at IVS3-
IVS4 region are detected in either brain or heart. Many of the variations have not been reported in 
the literature. For each locus, the schematic of the splicing mechanism is demonstrated by the 
splicing out of the introns (highlighted in grey) and the joining of the exons (open boxes) to 
produce the mature transcript represented by linked boxes of the various exons. Splice variations 
are displayed by the numbering of the exons in the boxes and splicing of alternate exons is shown 
to have occurred when the numbering of the exons is not in numerical sequence. Splicing at 
alternate donor or acceptor junctions is indicated by a dotted vertical line across the exon box. 
Splice variants in human α11.2 subunit detected in this study and reported in the literature are 
indicated by “+”, while those variants that are not detected in this study or reported elsewhere are 
indicated by “-”. The cDNAs screened were generated from these tissues: HAB – human adult 
brain; HFB – human fetal brain; HAH – human adult heart; HFH – human fetal heart. The known 
human splice variants have been reported by (a) Blumenstein et al (2002); (b) Soldatov NM 
(1992); (c) Abernethy et al (2002); (d) Schultz et al (1993); (e) Perez-Reyes et al (1990); (f) Yang 
et al (2000); and (g) Soldatov (1994). 
 
 
3.2.1 Sixteen novel splice variations identified in human α11.2 subunit 
 Sixteen splice variations in the human α11.2 subunit transcript found in this study 
are novel variations. They are listed as follow: (1) a new 120-nucleotide insert named 10* 
was found between exon 10 and 11; (2) a 75-nucleotide insert named exon 9* was 
identified between exon 9 and 10, corresponding to the similar insertion found in rabbit 
lung, mouse brain and rat smooth muscle cell line A7R5 (Biel et al., 1990; Ma et al., 
1992; Bielefeldt, 1999). As shown in Fig. 3.4, both exon 10* and exon 9* were in-frame 
inserts when analysed by DNAstar programme (Madison, WI); (3) a 4-nucleotide 
(TCAG) insert between exon 2 and exon 3; (4) a 9-nucleotide (ACTGGCCAG) or 12-
nucleotide (CTGACTGGCCAG) insert between exon 16 and exon 17. The insertion of 9-
nucleotide (9-nt) sequence (…ACTGGCCAG…) does not disrupt the reading frame 
while the insertion of 12-nt (…CTGACTGGCCAG…) gives rise to an in-frame TGA 
stop codon immediately 3’ of exon 16. The 12-nt insertion might produce a two-domain 
hemichannel as exon 16 resides on the II-III loop of α11.2 subunit; (5) the deletion of 
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both mutually exclusive exons 8 and 8a; (6) the combined deletion of exons 8a, 8 and 9 
together; (7) both deletion of mutually exclusive exons 21 and 22; and (8) 8 other splice 
variations found in IVS3 and IVS4 region which were generated from the complex 
combination of exons 31, 32 and 33 (Fig. 3.3B). 
 Exons 9* and 10* are novel having not been previously described for the human 
α11.2 subunit transcript. In addition to finding exon 9* in human heart, RT-PCR results 
from human aortic T/G HA-VSMC smooth muscle cells also showed that exon 9* was 
expressed in aortic smooth muscle (Fig. 3.5). It is notable that exon 10* was not 
annotated as a potential exon in the database but was detected by transcript-scanning in 1 
of 8 clones of amplicon 8-11 that were sequenced (Fig. 3.6). Essentially, the canonical 
splice sites and a pyrimidine tract flanking 10* confirm it as an exon. Their sequences 
were recently deposited in GenBank and the accession numbers are: exon 9*- AY562395; 
exon 10*- AY562396. 
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Fig. 3.4 Sequences of exon 9* and 10*. Exon 9* is a 75-nucleotide (75-nt) insert between exons 9 
and 10 while exon 10* adds 120-nt to the mRNA between exons 10 and 11 in the I-II loop of 
α11.2 subunit. The amino acid sequences they code were predicted by DNAstar programme. 
Their schematic alternative splicing patterns are also shown. 
 
 
Fig. 3.5 Identification of exon 9* in human aortic smooth muscle cells. RT-PCR results from 
human aortic smooth muscle cells T/G HA-VSMC. Lane 4 shows PCR results with different 
sizes. The sequencing results confirmed upper band containing exon 9* while lower band without 
exon 9*. Lane 5-8 served as the negative controls in RT-PCR reactions. Lane 1 and 2 are the 
positive controls to show the correct PCR results with exon 9* (lane 1) and without exon 9* (lane 
2). The templates used were the plasmid containing exon 9* in full-length CACNA1C 
(77WT+9*) in lane 1, and plasmid containing full-length CACNA1C but without exon 9* 
(77WT) in lane 2. Negative control using water as template was to rule out the contaminations. 
 




Fig. 3.6 Transcript-scanning PCR for exon  10*. A, examples of PCR from human adult whole 
brain cDNA library. The labels 8-11, 39-41, 48-50 indicated the exon regions covered by the 
respective PCR for human CACNA1C gene. B, colony PCR from the colonies transformed with 
exon 8-11 PCR fragments revealed individual bands with two sizes. The sequencing results 
confirmed that the higher band contained exon 10*. 
 
3.2.2 Extensive splice variations defined in human α11.2 subunit  
 Transcript-scanning has revealed 40 splice variations in the human α11.2 subunit 
transcript including 16 novel variations mentioned previously and 24 reported elsewhere 
(Soldatov et al). Predictably, a number of splicing events would produce non-functional 
channels: insertion of 4-nt at 5’ end of exon 3; deletion of 73-nt at 5’ end of exon 15; 
deletion of both 8 and 8a, or 8, 8a and 9; deletion of both 21 and 22; and the deletion or 
inclusion of both 31 and 32 (Fig. 3.3A and B). The 4-nt insertion at the 5’ end of exon 3 
shifts the reading frame of the α11.2 transcript. This would give rise to a premature stop 
with the production of only the N-terminus of the α11.2 subunit, and it would be 
interesting to determine if this short cytoplasmic fragment may play any dominant-
negative regulatory roles. What is also intriguing was the large number of splice 
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variations detected in the IVS3-S4 region where we identified all the 12 exon-
combinations derived from random inclusion or exclusion of exon 31/32, or 32-6nt and 
33. 
 The abovementioned alternative splicing patterns mostly followed the canonical 
alternative splicing GU-AG rule (Sharp and Burge, 1997) with 4 exceptions. The first 
exception was the insertion of 4-nt between exon 2 and exon 3 which employed the 
unconventional AU-UC splice sites. Interestingly, the second one is the the natural 
splicing occurring between exon 2 and exon 3 in CACNA1C. Based on the information 
from human genomic sequence, (NT_009759, gi:29805200), its alternative splicing 
patterns follow neither GU-AG nor AU-AC rule (Sharp and Burge, 1997). Instead, the 
splicesomes use the AU-AG as splice donor and splice receptor sites. The other two 
exceptions were the insertion of either 9-nt or 12-nt between exon 16 and exon 17 by 
using the unconventional GU-UG splice sites. 
 The transcript-scanning method has the limitation in screening the absolute N-
terminus and C-terminus of genes as the method requires flanking exons for the design of 
PCR primers. However, the first exon - exon 1a - has been found in human heart, rabbit 
heart, and rat (Mikami et al., 1989; Koch et al., 1990; Blumenstein et al., 2002; Dai et al., 
2002). For gathering comprehensive information of alternative splicing, we identified the 
exon 1a using its specific primers which were described by Blumenstein et al 
(Blumenstein et al., 2002). As the only exception in this study, exon 1a was identified by 
direct PCR instead of transcript-scanning. Although there was an exceptional report about 
finding exon 1a in brain by immunoblot study (Koch et al., 1990; Shistik et al., 1999), 
exon 1a is mainly found in heart and to a lesser extent in uterus and adrenal gland (Pang 
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Li, 2003). PCR using exon 1a specific primers showed that exon 1a exists in hearts but 
not in brains or aortas in our study (Fig. 3.7A).  
 
Fig. 3.7 Tissue specific expression of exon 1a and exon 45. A. PCR across 30-35 amplicon (lower 
panel) indicated the presence of Cav1.2 channels in human fetal and adult heart, aorta or brain.  
Exon-1a specific primers reveal exon 1a containing Cav1.2 channels (upper panel) present in 
human heart (Lane 1) and human fetal heart (Lane 2) but undetectable in human aorta (catalog #: 
7425-1, Marathon-Ready™ cDNA) (Lane 3), human adult whole brain (Lane 4) or human fetal 
brain (Lane 5). Lane 6 is the water control. B. Exon 45 was detected in Cav1.2 channels from 
human fibroblast cell line, Mrc5 (Lane 2) but not in human fetal brain (Lane 1), human adult 
heart (Lane 3) or human fetal heart (Lane 4). Instead, exon 45* was detected in all the tissues 
other than in human fibroblast cell line, Mrc5. However, its amount was far less than the major 
exon-combination (exon 44 + exon 46). 
  
 In all our scanning, we were unsuccessful in detecting exon 45 in human heart or 
brain but found that exon 45 was expressed at a high level in a human fibroblast cell line, 
Mrc5 (Fig. 3.7B). This observation agreed with the report of exon 45 detected in human 
fetal skin fibroblast cell line CRL 1475 (Soldatov, 1992). Instead, we detected exon 45* 
in the human heart and brain cDNAs, but not in fibroblast. However, the amount of splice 
variation with exon 45* insertion was far less than the major exon-combination (exon 44 
+ exon 46). We were also unable to detect the splice profile of the hippocampal cDNA 
clone h54 engineered into α1C,86 (Soldatov, 1994), which included the deletion of 17-nt 
from 3’end of exon 40 (40A), exon 40B, and the addition of 132-nt at the 5’end and 30-nt 
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at the 3’end of exon 43 (43A). However, such a cDNA clone might have been 
constructed from incompletely spliced nuclear pre-mRNA (Soldatov et al., 1997). 
 Altogether, we have identified 12 loci, 19 splice exons and 40 splice variations in 
the human α11.2 subunit (Fig. 3.1, Fig. 3.3A and B). This report, therefore, provides a 
comprehensive examination of all splice loci and splice combinations to highlight the rich 
repertoire of genetic variations in the human Cav1.2 channel. 
 
3.3 In-depth analysis of predominant splice combinations in IVS3-IVS4 
region 
 In the highly alternatively spliced region IVS3-IVS4 of CACNA1C, there could 
be as many as 12 different forms of variations.  The diversity in this region is due to 
transcripts generated by randomly used exon 31, 32 or 32-6nt and exon 33 (Fig. 3.3B). 
For a full understanding of the likely physiological impact of these splice variants, the 
relative expression levels and tissue distributions of these variants were studied. First, 
two colony libraries containing either PCR products of amplicon 30-35 (~500 bp) or 
amplicon 28-37 (~1240 bp) were generated and assessed to exclude the possibility of 
preferential PCR of one splice combination over another. More than 280 bacterial 
colonies of each recombinant cDNA library containing the IVS3-S4 region were screened 
for the usage of exons 31, 32, (32-6nt) and 33. Colony PCR by exon 31 and exon 32 -
specific primers was applied to identify the distribution of the variations in human brains 
and hearts. Both libraries provided corroborating results on the distribution of the IVS3-
S4 splice variants in the cDNA libraries examined. Based on PCR screening using exon 
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31 and 32-specific primers and validation by sequencing of 80 randomly picked colonies, 
we found exon 31 was expressed as the minor form at a low percentage in human fetal 
heart (13%), human adult heart (9%), human fetal brain (6%) and human adult brain 
(15%) cDNA libraries (Table 3 and Fig. 3.9). As exon 32 was the major form and it can 
consist of either the entire exon 32 or exon 32-6nt isoforms, the distributions of exon 32 
combined with exon 33 were studied in greater detail and the results are presented in 
Table 3.1, Figure 3.8 and 3.9. Of the 12 splice combinations, at least 5 were predicted to 
form functional channels (Fig. 3.9A and Table 3.3B). The result showed that the exon-
combination WT (-31+32+33) in IVS3-IVS4 region was the major form in human adult 
whole brain, fetal brain, and fetal heart cDNA. This splice combination represented 
between 59-66% of the clones screened (Fig. 3.9). There were, however, two co-
dominant isoforms in the adult heart which included 39% of WT (-31, +32, +33) and 
31% of variation C (-31, +32, -33). While on the other extreme, variation A (-31, +32-
6nt,-33) was detected at low levels representing between 1% in adult brain to 7 % in adult 
heart. Variation B (-31, +32-6nt, +33) was expressed at a more even level at between 11-
16% in all the cDNA libraries. The 3-fold increase in variation C (-31, +32, -33) of adult 
(31%) over fetal (10%) heart could have arisen by developmental regulation of exon 33. 
Interestingly, there is a 10-fold lower expression of variation C in adult brain when 
compared to adult heart pointing to a tissue or physiological difference in expression. A 
puzzling observation is that ~3-7% of the clones labelled as “others” either include or 
exclude the pair of mutually exclusive exons 31/32 which will likely generate non-
functional channels (Fig. 3.3B). The strict rule of mutually exclusivity in the inclusion or 
exclusion of either 31 or 32 did not apply in the α11.2 subunit transcript. Nonetheless, the 
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combination (+31,-32) was represented at between 8-16%, whilst the combination (-31, 
+32) range from 82-88% of the clones examined. The sequencing result also confirmed 
the distribution of the exon-combinations were consistent with the results from colony 
PCR screening. 
 
Fig. 3.8 Examples of the nested PCR method using exon 32 specific PCR reactions was applied to 
determine the distribution of splice variants in IVS3-IVS4 region in Human Adult Heart (HAH) 
cDNA library and Human Fetal Brain (HFB) cDNA library. The lanes labelled 1-6 indicated 
cDNA fragments of the 6 splice combinations (+31, +32, +33); (-31, +32, +33); (-31, +32, -33); (-
31, +32-6nt, +33); (-31, +32-6nt, -33) and (+31, -32, +33) were sub-cloned into pGEM-T Easy 
vector respectively and used as positive controls. In lane 7 H2O was used as negative control.  
The different splice combinations were differentiated based on their distinct migration patterns in 
4%-5% agarose gels. To verify the accuracy of the gel analysis, plasmids extracted from 





























WT (-31,+32,+33) 66% (2.6%) 62% (2.9%) 59% (2.64%) 39% (2.6%) 
A (-31,+32-6nt,-33) 3% (0.9%) 1% (0.6%) 2% (0.8%) 7% (1.4%) 
B (-31,+32-6nt,+33) 12% (1.8%) 16% (2.2%) 12% (1.7%) 11% (1.7%) 
C (-31,+32, -33) 6% (1.3%) 3% (1%) 10% (1.6%) 31% (2.5%) 
D (+31,-32, +33) 6% (1.3%) 15% (2.1%) 13% (1.8%) 9% (1.5%) 
others 7% (1.4%) 3% (1%) 4% (1.1%) 3% (1%) 
 
Table 3.1 Distributions of splice variations in the IVS3-S4 region in human fetal and adult hearts 
and brains. About 285-352 bacterial colonies containing amplicons 28-37 or 30-35 were screened 
for all 12 splice combinations (Fig. 3.3B). All the colonies were screened for inclusion or 
exclusion of exons 31 or 32 with the respective exon-specific primers and then collated to 
compute the distribution of the splice variations in the tissues. The values in parentheses are the 
Standard Deviation of the respective proportions. 




Fig. 3.9 Distribution of IVS3-S4 splice variations in fetal and adult heart and brain. A. 
Comparison of the amino acid sequences of the IVS3-S4 splice variations of WT and variations 
A-D.  B. The bar chart displays the predominant splice combination, WT (~60%), in fetal heart, 
and fetal and adult brain. Adult heart has two almost equal population of WT (39%) and C (31%) 
splice variations. “Others” includes the 7 rare splice variations listed in supp. Fig. B. The standard 
error of the distribution of each variation in a tissue is shown. Nclones is the number of colonies 
screened in each cDNA library. (Fetal Brain, Nclones = 334; Adult Brain, Nclones = 285; Fetal Heart, 
Nclones = 346; Adult Heart, Nclones = 352). The z-test was used to determine the statistical 
significance between the altered expression of variation D in brain and variations WT, A and C in 
heart, as indicated by “**” (p< 0.01). 
 
3.4 Construction of full-length α11.2 splice variants 
  The parental full length CACNA1C (α1C77WT) in pBluescript vector (Zuhlke et 
al., 1999) was kindly provided by Dr R.D. Zuhlke (Swiss Agency for Therapeutic 
Products, Switzerland). It contains the splice exons of 1-20, 22-30, 32-44, and 46-50. 
PCR fragments containing variation A (-31+32-6nt-33),  variation B (–31+32-6nt+33), 
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and variation C (-31+32-33) were amplified from adult heart cDNA libraries using 
primers No.23 and No.28, (Table 1) and variation D (+31-32+33) was amplified from 
fetal heart cDNA libraries using the same primers. The 4 splice variations were 
substituted into α1C77WT (-31, +32, +33) in pBluescript by using restriction enzymes 
BclI and BstBI. The various full-length human Cav1.2 containing splice combinations of 
the IVS3-IVS4 region were sub-cloned into pcDNA3 expression vector using restriction 
enzymes HindIII and XbaI. The human Cav1.2 splice variant clones were named α1C77-
A (-31, +32-6nt, -33), B (–31, +32-6nt, +33), C (-31, +32, -33) and D (+31, -32, +33). 
The identities of all the constructs were confirmed by DNA sequencing. The construction 
strategies and processes are shown in Fig. 3.10 and Fig. 3.11 respectively. 
 
Fig. 3.10 Schematic diagram of the constructions of α1C77WT and its variants. All variants were 
constructed in pBluescript SK- first by BstBI and BclI, and then sub-cloned into pcDNA3 by 
HindIII and XbaI.  
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Fig. 3.11 The procedure for constructing 77WT-A, B, and C. PCR fragments containing variation 
A (-31, 32-6nt, -33), variation B (-31, 32-6nt, +33), variation C (-31, +32, -33) were amplified 
from an adult heart cDNA library using primers No.23 and No.28 (Table 2.1). 
(1.) and (2.) The splice variations A, B and C were substituted into α1C77WT (-31, +32, +33) in 
pBluescript by restriction enzymes BclI and BstBI. (3.) The various full-length human Cav1.2 containing 
splice combinations of the IVS3-IVS4 region were sub-cloned into pcDNA3 expression vector using 
restriction enzymes HindIII and XbaI.(4.) Diagnostic digestion by HindIII and XbaI shows the correct 
digestion patterns of end products. The human Cav1.2 splice variant clones were named α1C77-A (-31, 
+32-6nt, -33), B (–31, +32-6nt, +33), C (-31, +32, -33) and D (+31, -32, +33). The identities of all the 
constructs were confirmed by DNA sequencing. 
 
3.5 Alternative splicing generates electrophysiological differences in 
Cav1.2 properties 
 
3.5.1 Distinctive I-V relationship of splice variants found in the IVS3-IVS4 region 
 Patch-clamp analysis was employed to characterize the biophysical properties of 
the splice variants. Fig 3.12 shows that the I-V relations of splice variants α1C77-A (-
31+32-6nt-33), α1C77-B (-31+32-6nt+33) and α1C77-C (-31+32-33) are shifted by 
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about 10-mV, 5-mV, or 7-mV in the hyperpolarizing direction with respect to that of 
α1C77WT (-31+32+33). All the three values of V1/2 were significantly different from 
that of α1C77WT variant (p<0.05).  In contrast, the α1C77-D (+31-32+33) did not 
exhibit a significant change of V1/2 when compared to α1C77WT, with only a 2.9-mV 
left shift in I-V curve (Table 3.2). 
Splice variants Erev V1/2 kI-V n 
α1C77WT 48.0±1.13 -9.3±1.28 -5.99±0.32 8 
α1C77-A 45.8±0.85 -19.4±0.96* -5.65±0.25 12 
α1C77-B 46.3±0.61 -14.3±0.60* -6.33±0.25 16 
α1C77-C 46.1±0.66 -16.7±0.96* -6.02±0.24 16 
α1C77-D 44.6±0.51 -12.3±1.12 -7.20±0.37 11 
 
Table 3.2 Parameters of current-voltage relationships of α1C77WT and splice variants. The I-V 
curves were fitted by IBa= Gmax(V-Erev)/{1+exp[(V-V1/2)/kI-V]}, where Gmax=maximum 
conductance, Erev=reversal potential, V1/2=voltage at 50% of IBa activation, and kI-V=slope factor. 
n= number of tested cells. *, p < 0.05 compared to the α1C77WT channel (one-way ANOVA and 
Tukey test). 







Fig. 3.12 Current-voltage relationships of α1C77WT and its splice variants. A. Exemplar test 
pulses of the WT and splice variants stepped from -90 mV to -50 mV, -30 mV, -10 mV,  0 mV or 
30 mV. B. A family of whole-cell currents recorded from human α1C77WT calcium channel or 
its splice variants with rat β2a and α2δ subunits in HEK293 cells. Ensemble of whole-cell I-V 
relationships were obtained by fitting the Boltzmann function. The whole-cell I-V relationships 
were obtained by holding the cell at -90 mV before stepping to various potentials from -50 mV to 
50 mV (∆V=10 mV) over 900 msec. V1/2 values and the numbers of the recorded cells for each 
splice variant are presented in Table 3.2. 
 
3.5.2 Distinctive steady-state activation of splice variants found in the IVS3-IVS4 
region 
To further examine the extent that splice variation affected the voltage-
dependence of activation, we performed tail-current analysis of the activation process, 
yielding G-V curves as shown in Fig 3.13. The channels were activated by a voltage 
family of 20-ms test pulses (-40 mV to 120 mV, ∆V=10 mV), and tail currents were 
measured after repolarization to -50 mV for 10 ms (Fig. 3.13A). The V1/2act of the splice 
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variants (Table 3.3) were significantly shifted in the hyperpolarization direction as 
compared to the α1C77WT by -11.2mV for α1C77-A, by -5.3 mV for α1C77-B and by   
-10.4 mV for α1C77-C. There was no statistical difference for the V1/2act when compared 
with the α1C77-D variant which contained equal IVS3-S4 linker length, even though 12 
of 28 amino acids coding for exons 31/32 are different.  
Compared to the I-V relationships, the tail-current analysis provides a more 
quantitative and rigorous assessment of activation properties. In fact, fits to these data 
indicated that the activation process was better described by a dual-Boltzmann 
characterization,   which only becomes obvious with the tail-current analysis. Half 
activation as determined by the dual-Boltzmann fits (V1/2act) confirmed the rank order of 
effects of splice variation on the voltage-dependence of activation.  
 
 3.5.3 The correlation between linker length and activation potential  
 There appeared to be a correlation between the IVS3-S4 linker length (Snutch et 
al., 1991) of the variants and the amount of hyperpolarizing shift of the voltage 
dependence of activation when compared to the WT (Fig. 3.13C). This is evident in the 
large shift in the V1/2act by -10 mV to -11 mV for a deletion of 11-13 aa compared to a 
smaller shift of 5 mV for a 2 aa deletion in the linker. Similar results are also 
demonstrated for the shift in I-V relationships. Absolute differences between V1/2 
(determined by qualitative I-V curve analysis) and V1/2act (determined from tail G-V 
analysis) are not surprising, given the limited, qualitative view of activation afforded by 
I-V curve data.  
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Splice variants V1/2    (mV) n 
α1C77WT 10.36±1.99 11 
α1C77-A -0.83±1.01 ** 7 
α1C77-B 5.09±1.36 * 10 
α1C77-C -0.02±1.16 ** 9 
α1C77-D 11.4±2.31 6 
 
Table 3.3 Activation parameters of α1C77WT and splice variants. V1/2 act is the potential for half-
activation calculated from dual-Boltzmann functions for steady-state activation when G = 
0.5Gmax. n = number of tested cells. *, p < 0.05, **, p< 0.01 when compared to the α1C77WT 
channel (Unpaired t test).   
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Fig. 3.13 Different human Cav1.2 calcium channel splice variants confer distinctive activation 
behavior to the L-type channels. A. Exemplar tail currents evoked by repolarizations to -50 mV 
after depolarizing test pulses at -40 mV, 0 mV, 40 mV or 90 mV. B. Ensemble of activation 
properties of α1C77WT and splice variants obtained from traditional tail-activation protocol. The 
channels were activated by a variable-voltage family of 20 msec test pulses, from -40 mV to 120 
mV, and tail currents were recorded on repolarization to -50 mV. Normalized (G/Gmax) vs. V 
curves were generated from a dual-Boltzmann function. V1/2act values and the numbers of the 
recorded cells for each splice variant are presented in Table 3.3. C. Correlation of IVS3-S4 linker 
length to hyperpolarized shift in I-V curve and voltage dependent activation of variants. The 
IVS3-S4 linker is estimated to be 24-aa long consisting of part of exon 31 or 32, the entire exon 
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33, and part of exon 34 (Stea et al., 1995). The IVS3-S4 linkers are either of the same length 
(variant D) or shorter by 13-aa (variant A), 2-aa (variant B) or 11-aa (variant C). 
 
 
3.5.4 No effect on steady-state inactivation of α11.2 alternative splicing 
The steady-state inactivation protocol involves eliciting a test pulse at 10 mV for 
30 ms that preceded a family of depolarising prepulses held for 15 seconds and then 
followed by another test pulse evoked at +10 mV for 104 ms. The voltage-dependence of 
steady-state inactivation of all the splice variants when assessed in comparison to the 
α1C77WT was found to be similar (Fig. 3.14). Their V1/2inact values were not statistically 
different as determined by the one-way ANOVA and Tukey tests (Table 3.4).  
 
Splice variants h(15s) V1/2 (mV) k n 
α1C77WT -39.14±2.43 -8.0±0.69 6 
α1C77-A -40.73±2.27 -8.2±0.69 6 
α1C77-B -42.25±1.34 -8.9±0.45 8 
α1C77-C -39.46±2.77 -9.2±0.79 8 
α1C77-D -39.98±1.17 -9.9±0.40 7 
 
Table 3.4 Steady-state inactivation parameters of α1C77WT and splice variants. Steady-state 
inactivation data were fitted by a Boltzmann function of the form: 
 h(15s)= I2/I1=(A1-A2)/{1+exp[(V-V1/2inact)/k]}+A2, where I2 is the test-pulse current, I1 is the 
normalization current, A1 is initial current amplitude, A2 is final current amplitude, V is the 
membrane potential of the conditioning pulse, V1/2 inact  is the potential for half-inactivation, and k 
is the slope factor. n= number of tested cells. *, p < 0.05 compared to the α1C77WT channel 
(one-way ANOVA and Tukey test). 
  




Fig. 3.14 Steady-state inactivation properties of Cav1.2 calcium channels are insensitive to splice 
variation at IVS3-S4 region. A. Exemplar current traces after 15s conditioning depolarizing pulses 
evoked at -120 mV, -90 mV, -60 mV, -40 mV or -20 mV. B. Ensemble of steady-state 
inactivation properties obtained from traditional steady-state inactivation protocol. The channels 
were evoked by the steady-state protocol in which a 30 msec normalizing pulse to 0 mV is 
followed by a variable-voltage family, from -120 mV to 20 mV, of 15-sec conditioning pulses 
and a 104 msec test pulse to 0 mV. Plots of the steady-state inactivation, h(15s),  as a function of 
voltage of conditioning pulse were obtained from normalized data points obtained from peak 
values of prepulse and test pulse currents [h(15s)=Itest/Iprepulse]. The smooth curves were generated 
from a single Boltzmann function. V1/2inact values and the numbers of the cells recorded for each 
splice variant are presented in Table 3.4.
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There were two major goals concerning the study of alternative splicing in the rat 
α11.2 gene. One was to identify the alternative exon-combination profiles in full-length 
α11.2 mRNAs in heart and aortic tissues, and the other was to determine whether the 
alternative splicing patterns of the α11.2 gene may change in response to hypertensive 
signals. In achieving the first goal, the full-length α11.2 splice variants in heart and aortic 
tissues from normotensive Wistar Kyoto rats (WKY rats) were constructed and analyzed. 
For achieving the second goal, alternative splicing of α11.2 transcripts in heart and aortic 
tissues at individual alternatively spliced exon level and in combination were compared 
between SHR and WKY rats. 
4.1 Characterizations of the animal models 
Initially, in order to verify the correct animal models were employed for 
subsequent molecular experiments, the physiological and pathological characteristics 
such as heart weight-to-body weight ratio, left ventricle weight-to-body weight ratio and 
blood pressure in 16-18 week SHR and WKY rats were examined before the heart and 
aortic tissues were collected.  
 SHR (n= 5) WKY (n=5) P value 
Systolic blood pressure (mm Hg) 195 ± 4.8 135 ± 7.6 P < 0.01 
Heart weight/body weight, (mg/g) 3.5 ± 0.4 2.8 ± 0.3 P < 0.01 
Left ventricle weight/body weight, (mg/g) 2.7 ± 0.3 2.0 ± 0.26 P < 0.01 
 
Table 4.1 Physiological and pathological characteristics of SHR and WKY rats. t-test was used to 
compare the statistical difference of systolic blood pressure, heart weight-to-body weight ratio 
and left ventricle weight-to-body weight ratio between SHR and WKY rats.   
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As summarized in Table 4.1, SHR had a 44% (p < 0.01) higher systolic blood 
pressure, a 25% (p < 0.01) increase in the heart weight-to-body weight ratio and a 35% 
increase in left ventricle weight-to-body weight ratio relative to age-matched WKY rats. 
These results confirmed the high blood pressure was fully developed and heart 
hypertrophy was initiated in 16-18 week old SHR (Yamori, 1994); The increases of both 
ratios suggest mild hypertrophy has been developed (Mukherjee and Spinale, 1998). This 
is consistent with the documented characters of age-matched SHR in which heart 
hypertrophy is at the beginning stage and gradually develops to concentric cardiac 
hypertrophy from 3 months to 12 months of age (Shorofsky et al., 1999). 
4.2 RT-PCR for full-length rat α11.2 cDNA 
4.2.1 Distribution of exon 1a and exon 1 in heart and aorta 
 In the human α11.2 subunit, exon 1a was found to be expressed only in heart but 
exon 1 was expressed in both heart and aorta (Fig. 3.7). Similar results were confirmed in 
rats as shown in Fig. 4.1 where exon 1a-specific primers yielded PCR products when 
heart cDNA was used. On the other hand, when exon 1-specific primers were used, both 
heart and aortic cDNA yielded PCR products. 






Fig. 4.1   Exon specific PCR was carried out to determine the distribution of exon 1a and exon 1 
by their specific primers. Lane 1-10 were the PCR results using exon 1a specific primers (No. 43 
and 44, Table 2.2). Lane 11-20 were the PCR results using exon 1 specific primers (No. 45 and 
46, Table 2.2). The template DNA used was listed below. In lanes 8, 9, 18, and 19, water was 
used as template for monitoring contamination. rbC-II cDNA which contains exon 1 but not exon 
1a was used as a negative control for exon 1a specific PCR reactions and as a positive control for 
exon 1 specific PCR reactions. 
 
Lane 1 and 11:  SHR 1 aortic cDNA 
Lane 2 and 12: SHR 2 aortic cDNA 
Lane 3 and 13: SHR 3 aortic cDNA 
Lane 4 and 14: SHR 4 aortic cDNA 
Lane 5 and 15: SHR 1 heart cDNA 
Lane 6 and 16: SHR 2 heart cDNA 
Lane 7 and 17: SHR 3 heart cDNA 
Lane 8 and 18: H2O 
Lane 9 and 19: H2O 




4.2.2 Full-length RT-PCR for rat α11.2 gene   
Importantly, the tissue specific distribution of exon 1a and exon 1 found in this 
study and by others (Dai et al., 2002; Pang et al., 2003; Tang et al., 2004) determined the 
full-length PCR for the rat α11.2 gene could be divided into three groups. In heart tissues, 
there were two kinds of full-length PCR products. One starts from exon 1a and ends in 
exon 50 (heart 1a-50 cDNA) and the other from exon 1 to exon 50 (heart 1-50 cDNA). 
While in aortas, only one kind of full-length PCR product was obtained from exon 1 to 
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exon 50 (aorta 1-50 cDNA). Since two strains of rats were examined in this study, a total 
of six different full-length cDNAs of the rat α11.2 subunit were obtained and analyzed. 
They were SHR heart 1a-50, SHR heart 1-50, SHR aorta 1-50, WKY heart 1a-50, WKY 
heart 1-50 and WKY aorta 1-50 cDNA. Examples of RT-PCR reactions of full-length 
α11.2 cDNA from different tissues and rat models are shown in Fig. 4.2- Fig. 4.4. The 
same type of full-length PCR products from 5 SHR or WKY rats were pooled together to 
generate a single full-length cDNA library. As the most important part of this study, 
constructions of first-strand cDNA and PCR for full-length α11.2 gene have been 
stringently tested in each rat sample. The positive and negative control tests were 
performed to ensure that spurious results are eliminated from the data, which are 
elaborated in the Materials and Methods section. 






Fig. 4.2 A. Examples of full-length PCR for exon 1a-50 in heart tissues from WKY rats and SHR. 
The upper primer was specific for exon 1a and the lower primer was a common sequence located 
at 3’-UTR of rat Cacna1c gene (No. 47 and 48, Table 2.2). The heart cDNA from individual rats 
labeled with WKY3, WKY4, SHR3, SHR4, and SHR5 et al were used as templates for full-length 
PCR reactions. The correct PCR products are about 6.5 Kb in size. “-ve” indicates the negative 
control PCR using RNA without reverse-transcriptase treatment instead of cDNA as template for 
respective cDNA samples. 
 
B. The results of the PCR fragments of full-length α11.2 gene cloned into PCR-XL vector 
digested by Hind III and Xba I. Only lane 1, 2, 3, 4 and 5 show the correct digestion patterns. The 
other lanes show the wrong digestion patterns which mean the full-length rat Cacna1c was not 
contained in the corresponding colonies. Five out of 16 colonies contained the correct plasmids. 
This picture typically reflected the low successful rates (15 - 30%) for construction the full-length 
Cacna1c PCR products into PCR-XL vectors. 
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Fig. 4.3 Examples of full-length PCR for heart 1-50 in heart tissues from WKY rats and SHR. 
The upper primer was specific for exon 1 and the lower primer was a common sequence located 
at 3’-UTR of rat Cacna1c gene (No.49 and 50, Table 2.2). The correct PCR products are about 
6.5 Kb in size. The template cDNAs were listed as below:  
 
1.  WKY1, heart cDNA 
2.   WKY2, heart cDNA  
3.  WKY3, heart cDNA 
4.   WKY4, heart cDNA 
6 and 7:  SHR 4, heart cDNA 
8 and 9:  SHR 5, heart cDNA 
-ve: the negative control PCR using mRNA  
without reverse-transcriptase treatment 
H2O:  negative control PCR without template DNA 
 
 
Fig. 4.4 Examples of full-length PCR for heart 1-50 and aorta 1-50 from WKY rat tissues. The 
upper primer was specific for exon 1 and the lower primer was a common sequence located at 3’-
UTR of rat Cacna1c gene (No.49 and 50, Table 2.2). The correct PCR products are about 6.5 Kb 
in size. The template cDNAs were listed as below:  
 
1.  WKY1, heart cDNA 
2.   WKY2, heart cDNA  
3 and 5  WKY1, aorta cDNA 
4 and 6  WKY2, aorta cDNA 
-ve: the negative control PCR using mRNA  
without reverse-transcriptase treatment 
Note:  The PCR product of lane 4 was not applied in the full-length cDNA library 
construction due to multiple bands were found in PCR products.  
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4.3 High specificities of exon specific colony PCR 
Another important part of this study was to achieve high specificities in exon 
specific colony PCR for 4 pairs of mutually exclusive exons. In general, exon specific 
colony PCR reactions were very specific. When one of the mutually exclusive exons 
showed positive PCR results, the other would show negative results (Fig. 4.5-Fig. 4.10). 
(As it was found in human α11.2 subunit, mutually exclusive exons of rat α11.2 were also 
not strictly mutually exclusive. In a few cases they could be both included or missing in 
the same full-length α11.2 clone). In the cases where both mutually exclusive exons are 
present in the same α11.2 clone, exon specific PCR results were both positive but one set 
of primers would produce a larger PCR product. But, when both mutually exclusive 
exons were absent, the PCR results were both negative (Fig. 4.11 and Fig. 4.12). These 



















Fig 4.5 Exon 8a specific PCR reactions were carried out in SHR and WKY heart 1a-50 cDNA 
colony libraries to identify the ratios of exon 8a and the inclusion of exon 9*. Upper panel is the 
colony PCR results for SHR heart 1a-50 library and lower panel is for WKY. The primers were 
No.51 and 52 in Table 2.2. The ratio of exon 8a was found to be 100% in both SHR heart 1a-50 
and WKY heart 1a-50 colony libraries. (The lanes without positive PCR results were later 
confirmed that the corresponding colonies didn’t contain full-length α11.2 gene). The bands with 
two sizes were observed in both panels. The sequencing result confirmed there was inclusion of 
exon 9* in the higher band and without exon 9* in the lower band. The negative controls using 
untransformed colonies as templates are indicated as “-ve”. 
 





Fig. 4.6 No exon 8 was found in heart 1a-50 cDNA libraries by exon 8 specific colony PCR. 
(primers No.53 and 54, Table 2.2). In 88 PCR reactions from SHR heart 1a-50 or WKY heart 1a-
50 cDNA clones, no exon 8 were found in either SHR or WKY rats. Eight positive controls were 
carried out in the same experiment to confirm the results. The lower bands in control reactions 
were the template cDNA without exon 9*, while the higher bands were the template cDNA with 
exon 9*. The negative controls using untransformed colonies as templates are indicated as “-ve”. 
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Fig. 4.7 Exon 8a specific colony PCR reactions showed exon 8a was the dominant exon 
in heart 1-50 cDNA libraries. The ratio of exon 8a was 57% in SHR heart 1-50 colony 
library and 73% in WKK heart 1-50 colony library. The bands with two sizes were 
observed in both panels. The sequencing result confirmed there was inclusion of exon 9* 
in the higher band and without exon 9* in the lower band. Only a few exon 9* were 
identified in this component. The negative controls using untransformed colonies as 
templates are indicated as “-ve”. 
 




Fig. 4.8 Exon 8 specific colony PCR reactions showed exon 8 was a minor variant (i.e. 
low representation exon) in heart 1-50 cDNA libraries. The ratio of exon 8 was 43% in 
SHR heart 1-50 colony library and was 27% in WKY heart 1-50 colony library. The 
bands with two sizes were observed in both panels. The sequencing result confirmed 
there was inclusion of exon 9* in the higher band and without exon 9* in the lower band. 
Exon 9* was more abundant than in Fig 4.7. The negative controls using untransformed 












Fig. 4.9 Exon 8a specific PCR reactions were carried out in SHR and WKY aorta 1-50 cDNA 
colony libraries to identify the ratio of exon 8a and the inclusion of exon 9*. Upper panel is the 
exon 8a specific colony PCR result for SHR aorta 1-50 library and lower panel is for the WKY 
aorta 1-50 colony library. The exon 8a was a minor variant. The ratio of exon 8a was 6% in SHR 
aorta 1-50 colony library and 2% in WKY aorta 1-50 colony library. In addition, no exon 9* was 
found in upper panel while 2 bands with exon 9* and without exon 9* were observed in lower 
panel. The negative controls using untransformed colonies as templates are indicated as “-ve”. 
 
  




Fig. 4.10 Exon 8 specific PCR reactions were carried out in SHR and WKY aorta 1-50 cDNA 
colony libraries to identify the ratio of exon 8 and the inclusion of exon 9*. Upper panel is the 
colony PCR result for SHR aorta 1-50 library and lower panel is for the WKY one. The figure 
shows exon 8 was the dominant exon in aorta 1-50 component. The ratio of exon 8 was 94% in 
SHR aorta 1-50 colony library and was 98% in WKY aorta 1-50 colony library. The negative 
controls using untransformed colonies as templates are indicated as “-ve”. 
  
4.4 Distinctive distribution of individual alternatively spliced exons in 
different tissues 
Significant changes of utilization of alternatively spliced exons of the α11.2 gene 
were observed for some exons when their distributions were examined in heart and aorta. 
Several interesting alterations in mutually exclusive exons were found. The exon 8a and 
exon 8 specific PCR reactions from the 6 full-length cDNA libraries are shown here to 
highlight the striking difference in their distribution in heart and aorta. Firstly, exon 8a 
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was 100% linked to exon 1a and no exon 8 was found in heart 1a-50 cDNA library (Fig. 
4.5 and 4.6). Secondly, exon 8a was also dominantly expressed in the heart 1-50 cDNA  
library whereas exon 8 exhibited much higher representation in the aorta 1-50 cDNA 
library (Fig. 4.7-Fig. 4.10). This dramatic difference in distribution of exon 8a and exon 8 
suggested that heart 1-50 could be a distinct full-length cDNA library. Thirdly, exon 9* 
was included in 3% of the α11.2 clones in the WKY heart 1a-50 cDNA library (Fig. 4.5 
lower panel) but was expressed at about 24-28% in heart 1-50 or aorta 1-50 cDNA library 
(Fig. 4.8 and Fig. 4.10, lower panels). 
 
 
Fig 4.11 Exon 21 specific PCR was carried out to determine the ratio of exon 21 in heart 1-50. 
The figure shows exon 21 was the dominant exon in heart 1-50 cDNA libraries. The figure shows 
the ratio of exon 21 was about 72% in SHR heart 1-50 colony library and was about 61% in 
WKY heart 1-50 colony library. The negative controls using untransformed colonies as templates 
are indicated as “-ve”. 
 






Fig. 4.12 Exon 22 specific PCR was carried out to determine the ratio of exon 22 and determine 
the ratio of (+21+22). The upper primer is in constitutive exon 17 and lower primer is specific for 
exon 22. The upper panel shows there were bands with 2 different sizes in SHR while there were 
bands with identical size in WKY heart 1-50. The sequencing result confirmed the higher bands 
contained both exon 21 and exon 22 (+21+22). The figure also shows exon 22 was the minor 
exon in heart 1-50 component. The ratio of exon 22 was about 35% in SHR heart 1-50 colony 
library and was about 39% in WKY heart 1-50 colony library. The negative controls using 
untransformed colonies as templates are indicated as “-ve”. 
 
 
Fig. 4.13, Fig 4.14 and Table 4.2 summarize the ratio of all the individual 
alternatively spliced exons in three cDNA libraries from heart and aorta tissues of WKY 
rats and SHR. The tissue specific distributions of individual alternatively spliced exons in 
SHR were generally similar to that in WKY rats, although there were some changes in 
individual alternatively spliced exons in SHR. The changes of individual alternatively 
spliced exons between SHR and WKY rats will be discussed later. Here, to illustrate the 
tissue specific distribution of alternatively spliced exons, the difference in expression 
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levels of the individual alternatively spliced exons of the three WKY cDNA libraries 











Fig 4.13 The alternative exons of rat α11.2 were compared among the three cDNA libraries in 
WKY rats. Exon 32 has a splice variant which deletes 6 nucleotides at the 3’-end of it (exon 32-
6nt), hence, exon32(-6nt) indicates the combined amounts of both splice variants. The detailed 
ratios of all exons are presented in Table 4.2. 
 
    
 
Table 4.2  The percentages of individual alternative exons in SHR and WKY rats 





Fig. 4.14 The alternative exons of rat α11.2 were compared among the three components in SHR. 
The ratios of all exons are presented in Table 4.2. The similar result of all exon ratios were 
observed in SHR compared to WKY rats except there was an up-regulated of exon 9* in heart 1a-
50 and aorta 1-50 cDNA library, and exon 33 were also up-regulated in SHR aortas. The detailed 
exon ratio comparisons between SHR and WKY rats were presented in Fig 4.22, 4.24 and 4.26.   
 
 
The major differences in expression levels of alternatively spliced exons among 
the three cDNA libraries are summarized as follows:  
(1) Expression of exon 8a was found to be dominant in heart, either in heart 1a-50 
(100%) or in heart 1-50 (73%), while the expression of exon 8 was dominant in aorta 1-
50 cDNA library (98%). 
(2) Expression of exon 22 was dominant in heart 1a-50 while exon 21was 
dominant in both heart and aorta 1-50. 
(3) Expression of exon 32 was predominant while exon 31 was represented at 
very low level in all the three cDNA libraries. The examples of colony PCR results from 
heart 1a-50 are shown in Fig. 4.15 and Fig. 4.16.  
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(4) For the alternatively spliced exons 9* and 33, exon 9* was represented in 3% 
of the α11.2 clones in the heart 1a-50 cDNA library but made up 24-28% of the α11.2 
clones in heart or aorta 1-50 cDNA library. Exon 33 was expressed at a very high level in 
the two heart cDNA libraries: with the ratio 98% in heart 1a-50 and 82% in heart 1-50. 
But its proportional representation in aorta 1-50 cDNA library was dramatically reduced 
to 57%.  
These results clearly showed that the usages of alternatively spliced exons in all 
three full-length α11.2 cDNA libraries were different from each other. Before showing 
the results of exon-combination profiles of full-length α11.2 clones, we examined 








Fig. 4.15 Exon 31 specific PCR reactions were used to determine the ratio of exon 31 in heart 1a-
50 cDNA libraries. It turned out exon 31 was a low representation exon or minor exon in heart. In 
a few cases, both mutually exclusive exon 31 and exon 32 co-existed in the same full-length 
clone. The example in upper panel shows there was a clone (+31+32+33) and the results were 
confirmed by DNA sequencing. The negative controls using untransformed colonies as templates 
are indicated as “-ve”. 
 





Fig. 4.16 Exon 32 specific PCR reactions were carried out to identify the ratio of exon 32 and the 
inclusion of exon 33. The upper panel shows the PCR result from SHR heart 1a-50 library and the 
lower panel shows the result from WKY heart 1a-50 library. The results show exon 32 was the 
dominant exon in heart 1a-50. Sequencing results confirmed that higher bands contained exon 33 
and lower bands were without exon 33. Please note very few clones were without exon 33. The 
negative controls using untransformed colonies as templates are indicated as “-ve”. 
 
4.5 Linkages of alternatively spliced exons revealed by assessment of 
identities of full-length α11.2 clones 
Certain linkages in the inclusion or exclusion of alternatively spliced exons in 
α11.2 clones were obvious in this study. In theory, the random chance that any 
alternatively spliced exon (either mutually exclusive exons 8/8a, 21/22 and 31/32 or 
alternative exons 9* and 33) is included in a full-length α11.2 clone should be 50%. The 
only exception is exon 1 or exon 1a. It needs to be noted that the probability of inclusion  
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of exon 1a or exon 1 is always 100% in their respective cDNA libraries. Therefore, the 
theoretical probability that exon 1 will be expressed together with either exon 8 or 8a 
should be (100%*50% = 50%). When three alternatively spliced exons are considered 
together, for instance, the theoretical probability that (exon 1+ exon 8 – exon 33) 
combination occurs should be 25% (100%*50%*50% = 25%) in either heart 1-50 or 
aorta 1-50 cDNA library. Here, a linkage is designated when the actual frequency of the 
alternatively spliced exons spliced together is significantly higher than the theoretical 
probability that these exons are randomly spliced together. The five linkages have been 
observed in this study and they are summarized in Table 4.3. 
 
Table 4.3 Exon-linkages of alternatively spliced exons of α11.2 subunit revealed in the three 
WKY cDNA libraries. z-test was applied to compare the observed frequency of a linkage with its 
theoretical probability. Only the exon-combination with a significantly higher observed frequency 
than a theoretical one is considered as a linkage. (#) indicates that the observed frequency of an 
exon-combination is lower than its theoretical probability, hence it is not considered as a linkage. 
 
  
The first and strongest linkage is (exon 1a + 8a). When there was exon 1a, the 
α11.2 clone would also contain exon 8a. The frequency of occurrence for this linkage was 
100% based on analysis of 192 clones from the SHR and WKY heart cDNA libraries 
while a theoretical probability is 50%. To extend this linkage in full-length profiles, the 
strong linkage in heart 1a-50 was (exon 1a + 8a - 9* + 32 + 33), the frequency of its 
occurrence was 94% when exon 32-6nt is considered as a special form of exon 32 (Fig 
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4.13 and Fig 4.14). The theoretical frequency for this linkage is 6.25% 
(100%*50%*50%*50%*50% = 6.25%). 
The second linkage was not as obvious as the first one. It was the linkage between 
exon 8 and exon 9* occurring in heart 1-50 cDNA library. It could only be noticed by 
detailed comparative study of occurrence of exon-combinations (exon 8+9*) and (exon 
8a+9*) in heart 1-50 cDNA libraries (Fig. 4.7 and Fig. 4.8.). The linkage (exon 8 + 9*) 
was only identified in a sub-population of α11.2 clones containing exon 8 in heart 1-50 
library. The ratio of (exon 8+9*) was 80% in the 25 clones containing exon 8 (i.e. 20 
α11.2 clones containing (exon 8 + exon 9*) out of 25 clones which include exon 8). 
However, the theoretical probability for either (exon 8 +exon 9*) or (exon 8- exon 9*)  
should be 50% (100%* 50%=50%) instead of the 25% (50%*50%=25%) in this case, 
due to the fact that only a sub-population of α11.2 clones containing exon 8 were 
analyzed. 
The third linkage was the one between exon 1a, exon 8a and exon 22. In WKY 
heart 1a-50 cDNA library, the percentage of α11.2 clones containing (exon 1a +8a + 22) 
was about 62% (Table 4.3, Fig 4.13 and Fig 4.14), which is significantly higher the 
theoretical probability 25%.   
The fourth linkage was opposite of the third one. It was the linkage between exon 
1, exon 8 and exon 21 which was found in aorta 1-50 cDNA library. The observed ratio 
of occurrence for this linkage (exon 1 + 8 + 21) was 75% in WKY rats (Table 4.3, Fig. 
4.13 and Fig. 4.14), which is significantly higher than the theoretical probability 25%. 
The fifth linkage was the linkage between exon 32 and exon 33 which varied in 
different tissues. In theory, a random linkage between these two exons should be 
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(50%*50%=25%). In fact, it was very strong (94%) in heart 1a-50 as mentioned above. 
In heart 1-50, this linkage was about 70%, and in aorta 1-50, the linkage was 54% (Table 
4.3). 
4.6 Exon-combinations in 6 full-length cDNA libraries 
In our previous transcript-scanning of the human α11.2 gene, we observed 19 
exons that were subjected to alternative splicing. Here, we have managed to analyze 
exon-combinations based on 10 alternatively spliced exons that likely generate functional 
channels. These exons include 8 mutually exclusive exons 1a/1, 8a/8, 21/22, 31/32 or 32-
6nt and 2 alternative exon 9*, exon 33. In the 9 exons not analyzed here, exon 9 is 
represented 100% in 689 full-length rat clones analyzed so it should be regarded as a 
constitutive exon. Even though we found the splice variation with deletion of exon 8,  
exon 8a and exon 9 together in human tissues, it is probably from improperly spliced pre-
mRNA products. Exon 10*, exon 45* and exon 45 were not found in rat full-length 
clones, which may be due to the limitation of 689 full-length clones obtained or the 
different alternative splicing patterns between species. Interestingly, exon 10* is only 
found in human hearts and brains and has never been reported in other species. It is 
reasonable that minor exons (i.e. alternative exons with low representation) may not be 
found in the limited number of full-length α11.2 clones examined. For example, the 
amount of PCR product containing exon 45* in human heart tissues was barely detectable 
and was expressed at a much lower level than the variation without exon 45* (Fig. 3.7). 
Another example is exon 45 in which the study by Klockner et al showed exon 45 is 
about 2% in heart and aortic tissues. Therefore in full-length cDNA population, the exon-
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combinations containing exon 45* and exon 45 would likely be too diluted to be detected 
in 689 full-length clones from rats. The expression of the other 5 spliced variations such 
as the 4nt-insertion between exon 2 and 3, the 12-nt deletion in exon 7, the 73-nt deletion 
in exon 15, and the 9-nt/12-nt insertions between exon 16 and 17 are generally very low 
varying from 0-10% in our preliminary study.   
The full-length exon-combination analysis is mainly based on the linkages of 10 
of the more highly represented alternatively spliced exons. Based on the combinations of 
8 mutually exclusive exons 1a/1, 8a/8, 21/22, 31/32 or 32-6nt and 2 alternative exon 9*, 
exon 33, a total of 64 exon-combination patterns were identified in this study. This 
number is much smaller than the theoretical one, 3×29 = 1536 (here, exon 32, exon 32-
6nt and -exon 32(-6nt) are three choices in IVS3 segment). The full-length exon-
combinations in rat α11.2 subunit are summarized in Table 4.4. Splicing patterns were 
named Variant 1 (V1) to Variant 64 (V64). The schematic exon-combinations of 
representative Splice Variants which were found to be dominantly expressed in WKY 
cDNA libraries are shown in Fig. 4.17. 
 The highly complicated exon-combination patterns require a system to encode 
them for easy reference. Here is the coding system used in Table 4.4: each alternative 
exon is given a value, and then the exon combination patterns are coded in a mathematic 
value by summing all the values assigned to specific alternatively spliced exons. For 
example, 70000 is for exon 8a;   80000 for exon 8; 0000 for without exon 9*; 9000 for 
inclusion of exon 9*; 100 for exon 21; 200 for exon 22; 000 for without both exon 21 and 
22; 10 for exon 31; 20 for exon 32; 60 for exon 32-6nt; 0 for without exon 33 and 3 for 
inclusion of exon 33. The exception is exon 1a and exon 1, in which exon 1a is coded by 
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“A” and exon 1 by “B”.  Hence, the exon combination is the sum of all these values of 
specific exon and they are prefixed by either “A” (exon 1a) or “B” (exon 1). For 
examples, A79223 stands for exon-combination form (exon 1a, 8a, 9*, 22, 32, 33),  
B80310 stands for (exon 1, 8, -9*, 21, 22, 31, -33), and B70263 stands for (exon 1, 8a, -
9*, 22, 32-6nt, +33) and so on.  




Fig. 4.17 The schematic exon-combinations of representative splice variants which were found to 
be dominantly expressed in WKY cDNA libraries. Only 10 alternatively spliced exons examined 
in rat full-length α11.2 cDNA libraries are shown. The constitutive exons and other potential 
alternatively spliced exons are represented by the lines. The dominantly expressed exon-
combinations from three full-length α11.2 cDNA libraries (heart 1a-50, heart 1-50 and aorta 1-50 
cDNA libraries) are indicated respectively.  
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Table 4.4  Exon-combination profiles in SHR and WKY rats 
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The numbers of exon-combinations of the α11.2 subunit in each cDNA library are 
presented in Fig. 4.18. Many exon-combinations were identified in more than one full-
length cDNA library. To combine the number of exon-combinations in the same library 
from SHR and WKY rats, there were 13 exon-combinations found in heart 1a-50 (V1-
V13); 29 exon-combinations in heart 1-50 (V14-V42); and 39 in aorta 1-50 (Fig. 4.19). 
Between heart 1-50 and aorta 1-50 cDNA libraries, 22 exon-combinations were unique in 
aorta 1-50 (V43-V64) and 12 were unique in heart exon 1-50 (V20, V24-26, V29-30, 
V32, V34-35 and V40-42). Hence, 17 exon-combinations overlapped in both heart 1-50 
and aorta 1-50 cDNA libraries. They were V14-19, V21-23, V27-28, V31, V33, and 
V36-39. However, the distribution of these 17 overlapping exon-combinations was 
different in heart and aorta. This is shown in the following section. 
 
 
Fig. 4.18 Summary of the numbers of exon-combinations in full-length rat α11.2 subunit. The 
numbers of exon-combinations from each cDNA library are indicated at the top of the respective 
bars.  
 




Fig. 4.19 Summary of numbers of exon-combinations of Cav1.2 α1 subunit (α11.2) in heart and 
aortic tissues. There were 13 exon-combinations (V1~V13) in Heart 1a-50 cDNA libraries 
(include both libraries from SHR and WKY rats). They were only present in hearts and unique in 
containing exon 1a. 29 exon-combinations were found in heart 1-50 cDNA libraries (V14~V42) 
and 39 ones were found in aorta 1-50 cDNA libraries. Between these two groups, 17 exon-
combinations were found to be overlapped. Therefore, in total 42 exon-combinations were found 
in hearts and 39 were found in aortas. 
 
4.7 Distinctive profiles of exon-combinations of α11.2 cDNA libraries 
generated from different tissues 
The proportional representations of the 17 overlapping exon-combinations were 
obviously different in heart and aorta as shown in Fig. 4.20. In WKY heart 1-50 cDNA 
library, V14, V15 and V16 were the main exon-combinations and their ratios were 
significantly higher than those in aorta 1-50 cDNA library (p< 0.01). On the contrary, 
V21, V28 and V27 were dominant exon-combinations in aorta and their proportions were  
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significantly higher when compared to their expression in heart 1-50 cDNA library (p< 
0.01 or 0.05).  In addition, 25 exon-combinations in total were found in SHR heart 1-50 
while only 19 were identified in WKY heart 1-50 cDNA library (Fig. 4.18).  
In SHR heart, V14 and V15 were the major exon-combinations and their proportions 
were represented significantly lower in aorta. In contrast, V21, V18 and V28 were main 
exon-combinations in aorta and the ratios of V21 and V28 were much higher than those 
in hearts (Fig. 4.21).  
In heart 1a-50, V1-V13 α11.2 exon-combinations containing exon 1a are unique. 
Therefore, the tissue specificity of exon-combinations was clearly demonstrated in three 






Fig. 4.20 The dominant exon-combinations of exon 1-50 from heart and aorta tissues in WKY 
rats are compared. The difference between two exon-combination profiles is clear. Variants 14 
(29%), 15 (23%), and 16 (9%) were the major components in hearts, while variants 21(26%), 28 
(18%) and 27 (9%) were dominant in aortas. The alteration of the same variant between two 
strains was compared by z-test (**, p < 0.01, * p < 0.05). 
 




Fig. 4.21 The dominant exon-combinations of exon 1-50 from heart and aorta tissues in SHR are 
compared. The difference between two exon-combination profiles is clear. Variants 14 (22%), 15 
(13%), and 18 (9%) were the major components in hearts, while variants 21(22%), 18 (14%) and 
28 (9%) were dominant in aortas. The alteration of the same variant between two tissues was 
compared by z-test (**, p < 0.01, * p < 0.05). 
 
 
4.8 Altered utilization of individual alternatively spliced exons and 
exon-combinations in hypertension 
Both individual alternatively spliced exons and exon-combinations of the α11.2 
subunit were found to be dramatically altered under hypertensive conditions. Here, the 
changes of alternative splicing of rat α11.2 gene in SHR and WKY rats were compared 
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4.8.1 Comparison of individual alternatively spliced exons and exon-combinations in 
heart 1a-50 
Fig. 4.22 summarizes the comparison of all the individual alternatively spliced 
exons from the heart 1a-50 cDNA library of SHR and WKY rats. Exon 9* was 
significantly up-regulated from 3% in WKY rats to 11% in SHR. The original gel photo 
clearly demonstrates this trend (Fig. 4.5). 
The exon-combinations of heart 1a-50 from SHR and WKY rats are shown in Fig. 
4.23 and Table 4.4. The two dominant exon-combinations were V1 and V2 in SHR and 
WKY heart tissues. Distributions of the other 11 exon-combinations either from WKY or 
SHR range from 13% to 1% (Table 4.4). V1 (33%) in SHR was significantly lower than 
that in WKY (50%) although the other two exon-combinations, V4 and V8, were up 
regulated in SHR. These changes were statistically significant (p< 0.05, z test). V4 is 
similar to V1 and the only difference between them is that 6 nucleotides are deleted from 
exon 32 at the 3’end. It was up-regulated from 4% in WKY rats to 12% in SHR. V8 was 
increased from 2% in WKY rats to 11% in SHR. It needs to be noted that the ratios of 
exon 32-6nt in SHR vs. WKY rats were not compared in individual exon comparison 
where they were designated as exon 32(-6nt) group.






Fig. 4.22 The individual alternatively spliced exons in SHR and WKY heart 1a-50 cDNA 
libraries were compared. There was only one exon change identified. Exon 9* was up-regulated 
approximately 3 times from 3% in WKY rats to 11% in SHR. The change was significantly 





Fig. 4.23 All 13 heart 1a-50 exon-combinations of rat α11.2 from SHR and WKY rats were 
compared. The dominant exon-combination was V1 in both SHR (33%) and WKY rats (50%). 
The reduced V1 was compensated by the increased V4 in SHR. In addition, there was a 
significant increase in V8 in SHR compared to WKY rats (*, p < 0.05). The ratios of many exon-
combinations (V6-V13) were less than 5% and they were not able to be statistically studied due to 
the insufficient counts. 
 Chapter IV Results: Full-length exon-combinations of rat α11.2 subunit  
 95
4.8.2 Comparison of individual alternatively spliced exons and exon-combinations in 
heart 1-50 
The changes in expression of the individual alternatively spliced exons between 
SHR and WKY heart 1-50 are shown in Fig. 4.24. Significant changes in the distribution 
of exon 8a and 8 were observed and no expression of other exons were significantly 
altered. However, in addition to the alterations of distribution of exon-combinations, 
many unique splice variants were found in SHR as compared to WKY rats. The major 
exon-combinations and the comparison study of heart exon 1-50 cDNA libraries in SHR 
vs. WKY are shown in Fig. 4.25. V14 and V15 were the dominant exon-combinations in 
both SHR and WKY. The significant changes in alternative splicing profile were found in 
V15 and V33. It seemed the reduced portion of V15 in SHR was partially replaced by an 
increased V33. The proportion of V15 is reduced from 22% in WKY to 13% in SHR, 
while V33, which was not found in WKY, now comprised 6% of the full-length cDNA 
clones examined in SHR heart. Interestingly, even though only the distributions of exon 
8a and exon 8 were altered, the difference of exon-combinations between SHR and WKY 
were far beyond exon 8a and exon 8. The changes in alternative splicing patterns should 
contribute to this contradiction. Fig. 4.12 demonstrates that the alternative splicing 
patterns were changed in exon 21 and exon 22. As a result, WKY had 19 exon-
combinations while SHR had 25 combinations (Table 4.4). Among these 25 










Fig. 4.24 The individual alternatively spliced exons in SHR and WKY heart 1-50 cDNA libraries 
were compared. There was a switching in ratios of mutual exclusive exon 8a and exon 8 from 
SHR and WKY rats. Exon 8a was down-regulated 16% from 73% in WKY rats to 57% in SHR. 
On the contrary, exon 8 was up-regulated 16% from WKY rats (27%) to SHR (43%). The 





Fig. 4.25 The main heart 1-50 exon-combinations of rat α11.2 from SHR and WKY rats were 
compared. The dominant exon-combination was V14 in both SHR (22%) and WKY rats (29%). 
There was a reduced ratio in the 2nd dominant variant V15 in SHR (13%) compared to that in 
WKY rats (23%). While other major variants (V16, V17, V18 and V21) were not significantly 
changed, the V33 was a novel exon-combination observed in SHR (6%) and was not found in 
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4.8.3 Comparison of individual alternatively spliced exons and exon-combinations in 
aorta 1-50 
The changes of all alternatively spliced exons in aorta 1-50 from SHR and WKY 
rats are compared in Fig. 4.26. Expression of exon 9* was higher in SHR (38%) than in 
WKY rats (24%). As well, the expression of exon 33 was increased 18% in SHR (75%) 





Fig. 4.26 The individual alternatively spliced exons in SHR and WKY aorta 1-50 cDNA libraries 
were compared. A significant difference was observed in exon 9* and exon 33. Exon 9* was up-
regulated 14% from 24% in WKY rats to 38% in SHR. As well, the exon 33 was up-regulated 
18% from WKY rats (57%) to SHR (75%). 




Fig. 4.27 Exon 32 specific PCR was carried out to identify the ratio of exon 32 and the inclusion 
of exon 33. The upper panel shows the PCR result from SHR aorta 1-50 library and the lower 
panel shows the result from WKY aorta 1-50 library. Sequencing results confirmed that higher 
bands contained exon 33 and lower bands were without exon 33. The percentage of exon 32 was 
91% in SHR aorta 1-50 and was 92% in WKY aorta 1-50 cDNA library. Exon 32 was the 
dominant exon in aorta 1-50. In addition, the percentage of inclusion of exon 33 was 75% in SHR 
aorta 1-50 and 57% in WKY aorta 1-50 colony library. The negative controls using 




In addition to the changes in individual alternatively spliced exons, α11.2 exon-
combinations were also altered in aorta 1-50 cDNA libraries in SHR as compared to 
WKY rats (Fig. 4.28). V21, V28, V27 and V18 were dominant in both SHR and WKY 
rats, although the ranking of the dominant exon-combinations were different in SHR as 
compared to in WKY rats (Table 4.4). V28 was significantly lowered in SHR (9%) when 
compared to in WKY (18%) (p = 0.028). The proportion of V18 was 7% in WKY which 
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was half of the 14% seen in SHR. However, this is a directional change and was found 
not to be statistically significant (p = 0.092). Similar to the observation for heart 1-50 
cDNA libraries, the dramatically different numbers of exon-combinations were observed 
in aorta 1-50 cDNA libraries in SHR and WKY rats. There were 20 exon-combinations in 
WKY rats while 36 in SHR. Between these two groups, 17 of them overlapped. Hence, 
19 combinations in SHR and 3 combinations in WKY (V19, V50 and V51) were 
different. 
The higher number of exon-combinations in SHR aorta 1-50 was not due to a 
greater number of colonies that were analyzed. In fact, after examining 100 colonies 
obtained from SHR, we observed 31 exon-combinations of SHR aorta 1-50 which were 
about 50% more than the 20 exon-combinations found in WKY aorta 1-50. The highly 
diversified categories of exon-combinations in SHR required us to analyze another 96- 
well plate of colonies for achieving the enough counts of major exon-combinations for 
statistical analysis. 





Fig. 4.28 The main exon-combinations of rat α11.2 from aortas of SHR and WKY rats were 
compared. The dominant exon-combination was V21 in both SHR (22%) and WKY rats (26%). 
There was a change in 2nd and 4th dominant variants in both strains. While V28 was the 2nd 
dominant exon-combination in WKY (18%), it made up 9% of full-length exon-combinations in 
SHR. V18 was the 4th dominant variant in WKY (7%), and it was up-regulated to the 2nd 
dominant variant in SHR (14%). The change in V28 was significantly different between strains 
(*, p < 0.05). The difference in V18 between both strains was only directional but not significant 
(p = 0.092). 
 
 
4.8.4 Aberrant splice variants were mainly found in SHR 
 
Interestingly, SHR aorta 1-50 had 15 unusual splicing variants. These aberrant 
variants contain both copies of the mutually exclusive exons such as exon 21 and exon 
22, or exon 31 and exon 32, or were missing both exons. In comparison, in WKY aorta 1-
50, only 3 of these unusual variants were identified (V43, V44 and V49).  
Among 64 exon-combinations, 22 of them were unusual variants in SHR. These 
aberrant splice variants were V3, V5, V13, V33, V38, V40, V42-V44, V49 and V52-V63 
(Table 4.4). There was an interesting correlation that all 22 variants were found in SHR, 
while only 5 of them were found in WKY rats (V3, V5, V43, V44 and V49). There were 
no aberrant variants found in WKY heart 1-50. A preliminary conclusion would  
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suggest that alternative splicing is prone to generate aberrant variants under hypertensive 
stress. Interestingly, the predicted proteins encoded by these aberrant variants are all in-
frame, without any premature stop codons. However, no functional expression study has 
been carried out to determine whether these channels are functional. It is probable that 
they are a result of mis-splicing of pre-mRNA and may not generate functional channels. 
Out of the 22 aberrant splice variants, 10 of them contained the (exon 21 + exon 
22) combination. Interestingly, in all three cDNA libraries, ratios of (exon 21 + exon 22) 
were obviously higher in SHR than in WKY rats (Fig. 4.29). More work is required to 
establish whether inclusion of both mutually exclusive exons 21/22 may be a common 
outcome of an altered alternative splicing system under hypertensive stress.   
 
Fig. 4.29 Comparison of percentages of (exon 21+ exon 22) combination in three full-length 
cDNA libraries from SHR vs. WKY rats. The (exon 21+exon 22) combination was higher in SHR 
than in WKY rats. The percentages difference in heart 1a-50 between SHR (10%) vs. WKY (3%) 
was not significant at 0.05 level but at 0.1 level. Therefore, a directional change was observed. 
On the contrary, significant changes for percentages of (exon 21+exon 22) were found in both 
heart 1-50 and aorta 1-50 cDNA libraries between SHR and WKY rats. (#, p = 0.064; **, p < 
0.01).  
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4.9 Summary of alternative splicing of α11.2 subunit in SHR and WKY 
rats 
Based on the comparative analyses of individual alternatively spliced exons and 
exon-combinations from three full-length cDNA libraries, it can be concluded that heart 
1a-50, heart 1-50 and aorta 1-50 cDNA libraries contained splicing patterns and 
combinations of α11.2 subunits that are different from each other. The differences of rat 
α11.2 alternative splicing between SHR and WKY rats have been demonstrated to change 
in some alternatively spliced exons, and more significantly in the splicing profiles of the 
α11.2 clones producing many unique exon-combinations in SHR tissues.







Discussion and Conclusion 
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Part I. Alternative splicing of α11.2 subunit in 
human brain and heart 
   
5.1 Systematic identification by transcript scanning revealed extensive 
splice variations of the human α11.2 subunit 
 In order to thoroughly examine all possible splice variations of α11.2 gene in 
human tissues, screening for alternative splicing of CACNA1C was for the first time 
carried out systematically in four human cDNA libraries in this study, and 16 novel splice 
variants were added to the repertoire of known splice variations of CACNA1C (Fig. 3.2 
and Figs 3.3A, B). Therefore, the number of identified splice variations of CACNA1C 
now amounts to 40. Among the 19 alternatively spliced exons, exon 1/1a have been 
reported to be derived by the activation of alternate promoters (Dai et al., 2002; Pang et 
al., 2003). Hence, 17 of the 55 exons in the α11.2 gene were subjected to alternative 
splicing, either by the inclusion or exclusion of the entire exon or at alternate splice 
junctions. Overall, the theoretical number of α11.2 splice variations produced by random 
splice decisions at each locus would be staggering (219 combinations for the α11.2 
subunit). This could support enormous diversity in channel functional properties.  
 On the one hand, transcript-scanning provided a quick glimpse of the possible 
splicing events for most of the exons in the α11.2 gene. On the other hand, owing to the 
numerous PCR reactions performed on 4 cDNA libraries as templates, we could only 
screen a limited number of bacterial colonies (8-32 colonies) and sequenced a small 
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number of PCR products showing different sizes (2-4 clones). It is possible that we might 
not have detected low abundant splice exons expressed in different tissues or 
developmental stages. However, as this study is conceivably the most comprehensive 
effort to systematically search for all the alternatively spliced exons of α11.2 subunit, this 
compendium of splice variations (Fig. 3.2 and Fig. 3.3A, B) should serve as a 
comprehensive reference library for future study.  
5.2 Potential functional consequences of various splice variants 
5.2.1 Alternative splicing at N-terminus of α11.2 subunit 
In the N-terminus, exon 1/1a has been reported to be derived by the activation of 
alternate promoters and we confirmed that the expression of exon 1a is cardiac muscle 
specific (Dai et al., 2002; Pang et al., 2003). PKC was shown to mediate the attenuation 
of the inhibitory effect of exon 1a via the phosphorylation of a channel site or auxiliary 
protein (Shistik et al., 1999). In addition, the role of the entire N-terminus fragment 
produced by the 4-nt insertion at the 5’ end of exon 3 requires further investigations. One 
possibility is that it may interfere with Gβγ-binding to the N-terminus or alleviate the 
inhibition of channel function (Shistik et al., 1998; Ivanina et al., 2000). 
 
5.2.2 Splice variations in Domain I and novel alternative exons in I-II loop 
In domain I, the junctional splicing at exon 7 would result in the deletion of 4-aa 
in the IS5-S6 P-loop region and how this may affect Ca2+ permeation is unknown. The 
exons 8/8a form the IS6 segment and this region affects the sensitivity of Cav1.2 channels 
to DHP block (Welling et al., 1997). In the I-II loop, we only detected exclusion of exon 
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9 together with exon 8 or 8a possibly giving rise to non-functional channels as IS6 (exon 
8/8a) and the alpha-interacting domain, AID, in exon 9 (Pragnell et al., 1994; Walker and 
De Waard, 1998) will be missing the protein will be translated out-of-frame with a 
premature stop.  
Exons 9* and 10* have not been reported in human α11.2 subunit. It has been 
hypothesized that exon 9* of the rat α11.2 subunit may be a target for phosphorylation 
(Bielefeldt, 1999). Exon 9* has been further studied in our laboratory, and it was found to 
be expressed more selectively in smooth muscle of arteries than in cardiac muscle or 
neurons. Electrophysiological study also demonstrated that the hyperpolarized shift in 
activation potential of exon 9* containing Cav1.2 channels could underlie the key shift in 
voltage activation parameters between smooth muscle and cardiac muscle cells (Liao et 
al., 2004). 
 
5.2.3 Possible generation of hemichannels from alternative splicing at Domain II 
and II-III loop 
There is the possibility that hemichannels, produced in the Cav1.2 α1-subunit by 
the deletion of 73-nt from exon 15 (domain II, P-loop) or the insertion of a 12-nt at the 5’ 
end of exon 17 (II-III loop), may act in a dominant negative fashion to dilute out β-
subunit interaction with the fully functional channels (Raghib et al., 2001). 
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5.2.4 Electrophysiological and pharmacological properties of Domain III and IV 
splice variations 
In the IIIS2 segment, the exons 21/22 imparted differences in the voltage-
dependence of DHP block on the Cav1.2 variants (Soldatov et al., 1995), while we have 
demonstrated that exon 31/32 (IVS3) did not produce different biophysical properties of 
Cav1.2 channels. Nonetheless, the combination (+31,-32) was represented at between 8-
16%, whilst the combination (-31, +32) ranged from 82-88% of the clones examined.  
Several studies in the rat and mouse also showed similar results (Snutch et al., 1991; 
Feron et al., 1994). However, a different distribution of exons 31 and 32 was reported in a 
human heart failure study (Yang et al., 2000).  In this study, it was shown that in non-
failing human ventricular myocytes splice variants containing exon 31 were about 2.5 
times more abundant than the variants containing exon 32 (Yang et al., 2000). This 
discrepancy could be due to the different tissue used in both studies. The tissue used by 
Yang et al was ventricular myocytes while whole heart cDNA libraries were used in our 
study.  
The deletion of 6-nt or 2-aa (-VN-) from exon 32 that resulted in a 5 mV 
hyperpolarizing shift of the I-V curve is reminiscent of the effect of a 2-aa insertion on 
the electrophysiological properties of the Cav2.1 and Cav2.2 channels (Bourinet et al., 
1999; Hans et al., 1999; Lin et al., 1999). The mechanistic generation of the 2-aa 
inclusion or exclusion is different as the -NP- and -ET- dipeptides are encoded on a 6-nt 
exon in the α12.1 and α12.2 subunit genes respectively, while the deletion of the 6-nt in 
α11.2 is via the use of alternate donor splice site. A number of splice variants in this locus 
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in different α1-subunits have been reported to display altered biophysical, biochemical or 
pharmacological properties (Bourinet et al., 1999; Abernethy and Soldatov, 2002; 
Lipscombe et al., 2002). 
α1C77-A and C both have about a 10 mV left-shift in I-V and G-V curves. It is 
interesting to note that both variants do not contain exon 33. The hyperpolarized shift of 
I-V curve and G-V curve suggests that the calcium channels would be more sensitive to 
electrical stimulation; it seems that the splice variants without exon 33 are more 
amenable to open upon slight depolarization of the membrane potential. The interesting 
finding that human adults have a higher percentage (31%) of variation C (-31+32-33) 
than that in fetal hearts (10%) may partially contribute to the differences in cardiac 
electrophysiology, e.g.  the longer cardiac action potential duration in adult heart (Garson 
et al., 1998). The altered channel behaviors of the IVS3-S4 splice variants may influence 
either the shape or the duration of ventricular action potentials similar to the mechanism 
proposed by Alseikhan et al (Alseikhan et al., 2002). This concept needs to be further 
verified by specific knock-out of exon 33 in Cav1.2 channels. In the future, transgenic 
mouse models could be employed to evaluate the biological consequences of the shifts in 
half-activation potentials arising from the splice variations of the IVS3-S4 in specific 
tissues.   
 
5.2.5 Alternative splicing at C-terminus of α11.2 subunit 
In the C-terminus, the EF-a and EF-b exons of Cav2.1 or Cav2.2 confer different 
Ca2+-dependent regulation, cell-specific localization or current density (Chaudhuri et al., 
2001; Bell et al., 2004). The α11.2 subunit, however, does not contain any mutually 
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exclusive EF-a or EF-b exon. Nonetheless, the insertion of the 57-nt at the 5’end of exon 
41 adds 19-aa to the pre-IQ3 region of the channel and how this may modulate the 
tethering of the calmodulin to the C-terminus of Cav1.2 and impact on Ca2+-dependent 
inactivation would have to be determined (Erickson et al., 2003). The deletion of 187-nt 
from exon 45* produces a truncated C-terminus which removes the serine PKA site in 
exon 48 (S1928) (De Jongh et al., 1996; Gao et al., 1997). To determine the physiological 
consequence of the junctional deletion at this low expressing splice exon would require 
further investigations. However, exon 45* has been implicated to be important for 
oxygen sensing (Schultz et al., 1993; Fearon et al., 2000). Interestingly, the role of exon 
45, expressed specifically in fibroblast, has not been characterized. 
5.3 Activation potential and IVS3-IVS4 linker length 
 Here, we have shown an extensive splice variation in the IVS3-S4 region that 
produced an apparent correlation of voltage-dependent activation to IVS3-S4 linker 
length, providing a basis for future in-depth investigations into structure-function 
relationships in channel activation. In Shaker potassium channels, the amount of shift in 
the voltage activation curves was not strictly proportional to the S3-S4 linker length but 
instead showed periodicity in half activation voltages (Gonzalez et al., 2001). One 
possible explanation for this discrepancy could be that the amino-acid sequence in the 
linker may also play a role in altering the biophysical properties. Our study, on the other 
hand, is based on native splice variants that produced correlative depolarizing half-
activation potential shifts to increasing linker lengths.  
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 Recently, Mackinnon and his colleagues proposed a novel channel-gating model 
for the voltage-gated potassium channel KvAP from the archaebacterium Aeropyrum 
pernix (Jiang et al., 2003b; Jiang et al., 2003a). From the X-ray crystal structure of KvAP, 
it was proposed that each S4 segments forms half of a ‘voltage-sensor paddle’ and the C-
terminus part of S3 together with the linker between S3 and S4, forms the other part of 
‘voltage-sensor paddle’. However, the ‘voltage-sensor paddle’ model is still 
controversial. Laine et al supports the conventional model which proposed that the S4 
helices move within protein lined pathways in their study of MthK channel (Laine et al., 
2003). As the locus of alternative splicing in the IVS3-IVS4 region is situated partly in 
‘the voltage-sensor paddle’ in the novel model or in the loop linking with ‘the voltage 
sensors’ in the conventional model, the observed linker length – activation potential 
relationship might be expected. The mechanism by which linker length of the IVS3-S4 
region modulates the gating properties of calcium channels requires future experiments to 
answer. Further study on other type of calcium channels to identify the similar alternative 
splicing forms will also be helpful to understand this design of nature. The 
electrophysiological difference of mutually exclusive exon 31 and 32 was not obvious in 
this study, and we think more subtly designed analyses may be needed to differentiate the 
functions of these two exons. 
5.4 Limitations of this study 
 We showed that exon 9* was expressed in low abundance in adult heart but not in 
brain, however, the transcript-scanning method did not provide information on the 
combinatorial profile of other alternatively spliced exons. Similarly, we demonstrated 
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developmental regulation of exon 33 in heart, but were unable to determine whether 
utilization of other alternatively spliced exons was changed in tandem. Even though the 
transcript-scanning method has uncovered novel and new splice variations, it may still 
not be able to detect rare splice variants or splice variants expressed in a cell-specific 
manner or under certain developmental or physiological states. 
5.5 Further study 
 Until now the physiological role of alternative splicing in CACNA1C gene has 
remained unknown. The different exon-combinations in CACNA1C have not been 
enumerated in different cell types, tissues, or in different physiological or disease 
conditions. The distribution of combinations of alternatively spliced exons in certain 
tissues or organs may vary dramatically. All these factors make the full understanding of 
functional roles of alternative splicing in CACNA1C difficult. Nonetheless, it is a 
consensus among many researchers that alternative splicing is an exquisite mechanism to 
generate functional diversity for Ca2+ channels. Our functional study of the α11.2 splice 
variants strongly supports this view. The usage of alternatively spliced exons may alter 
under pathological conditions, and several groups have reported such findings (Martin et 
al., 2000; Yang et al., 2000; Martin et al., 2002). More evidence is needed to support the 
idea. Furthermore, discovery of the pathological triggers that direct alternative splicing of 
a particular exon is of scientific interest and may be of clinical relevance. 
 A few questions are raised based on the information from this study. Firstly, what 
are the dominant combinatorial arrays of alternatively spliced exons of CACNA1C in a 
certain tissue or cell type?   It is very unlikely that there is only one splice combination in 
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one tissue, for a tissue often contains many different cell types. The study of alternative 
splicing of CACNA1C  in human fibroblasts by Soldatov NM and Cacna1c in rat smooth 
muscle cells A7R5 by Bielefeldt K showed that there is molecular diversity even in a 
single type of cell (Soldatov, 1992; Bielefeldt, 1999). 
 Secondly, what is the physiological role of the transcripts of CACNA1C that are 
deleted in both mutually exclusive exons or that contain an out-of-frame 
insertion/deletion? In this study, we uncovered transcripts which had deletions of both 
exon 8 and 8a, exon 21 and 22, exon 31 and 32, or which had a 4-nucleotide insertion 
between exon 2 and exon 3 or a 73-nucleotide deletion at the beginning of exon 15. On 
the one hand, it is probable that they are the products of randomly spliced CACNA1C 
transcripts that give rise to non-functional channels. On the other hand, they may play 
regulatory roles as hemi-channels. Raghib A et al demonstrated that hemi-channels may 
exert a dominant negative function in channel regulation (Raghib et al., 2001). In 
addition, Ebihara T et al showed that Cav1.2 protein lacking the N-terminus and the first 
domain specifically suppresses expression of Cav1.2 channels (Ebihara et al., 2002). 
Hence, the transcripts with both deletion of mutually exclusive exons or out-of-frame 
insertion or deletion may play a role in the regulation of wild-type Cav1.2 channel 
function. Further study is required to test this hypothesis in native cells rather than in a 
heterologous expression system.  
 Thirdly, what are the physiological or pathological triggers that are necessary to 
direct and commit the splicing of an alternative exon? The corollary is to understand the 
regulation of alternative splicing and to be able to monitor possible dynamic changes in 
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utilization of alternatively spliced exons for specific structural or functional channel 
diversity. 
 In part II of this study, we have tried to answer the first question by examining the 
exon-combinations of alternatively spliced exons of Cacna1c in heart and aortic tissues in 
rats, and the third question about the pathological triggers for regulation of alternative 
splicing of Cacna1c was further explored in Spontaneously Hypertensive Rats.   
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Part II. Alternative splicing of full-length 
α11.2 subunits in heart and aortic tissues 
from SHR and WKY rats 
 
To examine the splicing profiles of exon-combinations of α11.2 channels, we 
generated full-length cDNA libraries of α11.2 gene isolated from heart and aortic tissues 
of normotensive Wistar Kyoto Rats and Spontaneously Hypertensive Rats. This study 
took advantage of our knowledge of alternative splicing of human α11.2 gene to 
investigate the exon-combination profiles of alternatively spliced exons of the rat α11.2 
gene. For the first time, the tissue specific exon-combinations of α11.2 subunits in hearts 
and aortas were compared, and the changes of expression patterns, levels of individual 
alternatively spliced exons and exon-combination profiles in hypertension were revealed. 
This study would contribute substantially to our understanding on the extent and variation 
of alternative splicing of α11.2 gene at individual splice locus and on the possible number 
of exon-combination profiles in normotensive and hypertensive tissues. 
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5.6 Combinatorial assembly of alternatively spliced exons of α11.2 
subunit is generally linked and is not randomly arranged 
The huge number of possible exon-combinations of α11.2 gene based on 19 
known alternatively spliced exons poses a challenging question about the exact number 
of transcripts with genotypic variation in a tissue. In theory, the alternative exons in α11.2 
subunit found in our study and by others suggest the number of exon-combination could 
be as many as 219 based on the 19 splice variations found in human heart and brain (Tang 
et al., 2004). Here, we have managed to analyze 10 of them in our full-length exon-
combination study. The other 9 splice variations have not been analyzed here mainly due 
to their low distributions (1-10%) or because we could not find them in 689 full-length 
α11.2 clones analyzed. Our results demonstrated that the combinatorial utilization of 
alternatively spliced exons is generally linked and does not occur stochastically. 
Theoretically, based on 8 mutually exclusive exons 1a/1, 8a/8, 21/22, 31/32 or 32-6nt and 
2 alternative exon 9* and exon 33, there could be as many as 3×29 = 1536 kinds of exon-
combinations (here, exon 32, exon 32-6nt and (-exon 32(-6nt)) are three choices in IVS3 
segment). In reality, we only observed 64 exon-combinations in 689 full-length α11.2 
clones. At least two factors affect the number of exon-combinations: First, our study 
showed in certain tissues some alternative exons were dominantly expressed and some 
were in minority. The typical example is exon 1a which could be found only in heart but 
not aorta. In contrast, exon 32 is a dominantly expressed exon in both heart and aortic 
tissues while its mutually exclusive counterpart, exon 31, is the less represented exon. 
Secondly, alternatively spliced exons are linked in certain patterns. Hence, the actual 
number of exon-combinations will be dramatically reduced. One extreme example was 
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exon 1a and exon 8a linkage, their fidelity was 100% (Fig. 4.5, Fig. 4.6 and Table 4.3). In 
summary, we have so far identified 64 exon-combinations based on the assessment of the 
inclusion or exclusion of 10 alternatively spliced exons in the 689 full-length α11.2 
clones obtained from SHR and WKY heart and aorta. 
5.7 Three different cDNA libraries identified in rat heart and aorta 
5.7.1 Two promoters control three α11.2 cDNA libraries 
One of the major goals of this study is to determine the full-length exon-
combinations of α11.2 gene in cardiac and aortic muscle. Based on the differential 
distributions of exon 1a and exon 1, three full-length cDNA were identified in this study. 
Previous studies show exon 1a and exon 1 are controlled under different promoters (Dai 
et al., 2002; Saada et al., 2003). The 46-aa exon 1a is strongly and selectively controlled 
by a cardiac promoter while the 16-aa exon 1 is controlled by a ubiquitous promoter. In a 
detailed study by Pang et al, promoter activities for expression of exon 1a and exon 1 
have been tested in neonatal cardiomyocytes, cardiac fibroblasts, human aorta vascular 
smooth muscle cells and HEK293 cells. The results indicated that the promoter for 
activation of transcription in exon 1a only functions in cardiomyocytes while the 
promoter driving exon 1 is ubiquitously active in all of the above mentioned cells (Pang 
et al., 2003).  Therefore, this convincing evidence together with other studies 
demonstrates that exon 1a is mainly expressed in cardiomyocytes and to a lesser extent in 
uterus and adrenal gland. On the other hand, exon 1 is widely distributed in heart, brain, 
intestine, kidney and other tissues (Dai et al., 2002; Klugbauer et al., 2002; Pang et al., 
2003; Saada et al., 2003). Our study confirms that the expression of exon 1a is only in 
Chapter V Discussion 
 117
heart while exon 1 is expressed in both heart and aorta (Fig. 3.6 and Fig. 4.1). Based on 
this information, three full-length rat heart and aorta α11.2 cDNA libraries were 
constructed and analyzed for splice combinations in detail. The libraries were designated 
“heart 1a-50”, “heart 1-50” and “aorta 1-50” cDNA libraries. 
These three cDNA libraries are found to contain α11.2 clones that are 
dramatically different in their splicing patterns. They are distinct both in the 
representations of individual alternatively spliced exons and the identity of the profiles of 
exon-combinations in each library. The full-length α11.2 subunit exon-combinations and 
their linkages as characterized in the three cDNA libraries will be discussed in the 
following paragraphs. 
 
5.7.2 Heart 1a-50 cDNA library 
In heart 1a-50, the unique exon 1a in this cDNA library demonstrates it is a 
distinct cDNA library. Analysis of combinations of alternatively spliced exons showed 
clearly that the expression of some are linked. The observed frequency for the first and 
strongest linkage (exon 1a + 8a) was 100% based on analyzing 192 full-length α11.2 
clones derived from SHR and WKY hearts (Table 4.3). The possibility of getting this 
result by chance is very low (p = 2-192). This linkage is also clearly not due to the PCR 
contamination, for the other alternative exons like exon 21/22 or exon 31/32 from the 
same clones had variable linkages. An extension of (exon 1a + 8a) linkage in full-length 
cDNA was the linkage of (exon 1a + 8a - 9* + 32 + 33), with a percentage of 94% when 
exon 32-6nt were considered as a special form of exon 32. This result is different from 
the proposed “cardiac form”, α1C-a (1a, 8a, -9*, 31) (Welling et al., 1997). It is 
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noteworthy that the “cardiac form” of α1C-a (1a, 8a, -9*, 31) was a designation proposed 
by Welling et al to describe the α11.2 clone identified in rabbit heart by Mikami et al 
(Mikami et al., 1989). Furthermore, the proposed α1C-a (1a, 8a, -9*, 31) genotype was 
deduced from limited short-fragment clones obtained by the traditional screening of 
cDNA libraries which contain thousands of different genes. The shortcoming of such 
method is the limited assessment of the genetic profiles of a small number of clones. 
Hence, our study attempts to circumvent this limitation and to obtain a better 
understanding of exon-combinations of α11.2 gene in heart and aortic tissues. In this 
study, we found exon 32 is dominant both in human and rat hearts based on analysis of 
hundreds of clones containing short-fragments of CACNA1C gene obtained by RT-PCR 
of human tissues or containing rat full-length Cacna1c clones. Especially, full-length 
cDNA which is prefixed by exon 1a justifies the (exon 1a + 8a - 9* + 32 + 33) linkage to 
be the dominant exon-combinations of alternatively spliced exons in cardiomyocytes. 
Hence, to include the information about the other two alternative exons 45* and 45 which 
we have tested but not found in full-length α11.2 cDNA clones, we propose two more 
representative cardiac exon-combinations as indicated in V1 (1a, 8a, -9*, 22, 32, 33,-
45*,-45) and V2 (1a, 8a, -9*, 21, 32, 33, -45*, -45). V1 constitutes 50% and V2 
constitutes 25% of full-length α11.2 cDNA clones assessed in WKY heart 1a-50 cDNA 
library (Fig. 4.17, Table 4.4).  These two combinations constitute more than 75% of full-
length clones in WKY heart 1a-50 cDNA libraries. Compared to its mutually exclusive 
counterpart exon 21, exon 22 is dominant which constitutes about 62% in heart 1a-50 
full-length cDNA clones examined. Therefore, the dominant exon-linkages of heart 1a-50 
can be summarized as (1a, 8a, -9*, 22, 32, 33, -45*, -45).  
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5.7.3 Aorta 1-50 cDNA library 
In WKY aorta 1-50, the first and second dominant clones are V21 (1, 8, -9*, 21, 
32, 33, -45*,-45) and V28 (1, 8, -9*, 21, 32, -33, -45*,-45). V21 constitutes 26% and V28 
constitutes 18% of the full-length clones in the cDNA library (Fig. 4.17, Table 4.4). In 
regard to the theoretical smooth muscle form α1C-b (1, 8, 9*, 32) (Welling et al., 1993; 
Welling et al., 1997), it was represented by the 3rd dominant V27 (1, 8, 9*, 21, 32, -33, -
45*,-45) and 4th dominant V18 (1, 8, 9*, 21, 32, 33, -45*,-45) exon-combinations. The 
sum of both comprised only about 20% of the full-length clones in aorta 1-50 cDNA 
libraries. Therefore, there is discrepancy between the proposed exon-combination and the 
ones we observed. The reason would be the same as in heart 1a-50. The theoretical 
smooth muscle form α1C-b (1, 8, 9*, 32) is only a name proposed by Welling et al to 
describe the α11.2 sequence identified by Biel et al (Biel et al., 1990). The sequence was 
deduced from the limited number of fragmented clones isolated by traditional screening 
of cDNA libraries from rabbit lung. Therefore, it does not reflect the dominance of exon-
combinations of α11.2 gene in smooth muscle. Instead, the dominant splice variants in 
aorta 1-50 reported here is based on hundreds of full-length clones screened in rat cDNA 
libraries. Hence, we propose that the dominant splice variants of rat α11.2 gene in aorta 
are V21, V28, V27 and V18 (Fig. 4.17, Table 4.4). The summed ratios for these 4 splice 
variants are 60% in WKY 1-50 cDNA library. Their exon-linkages of alternatively 
splcied exons can be summarized as (1, 8, ± 9*, 21, 32, ± 33, -45*, -45). The (± 9*) and 
(± 33) mean both exon 9* and exon 33 can be included or excluded in the dominant 
exon-linkages. These exon-linkages of the α11.2 gene in aorta should mainly reflect the 
dominant exon-combinations of α11.2 gene in vascular smooth muscle. Here, the 
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structure of the aorta may need to be considered. Aortas are comprised of substantial 
amounts of smooth muscle cells and smaller number of fibroblasts. Even though 
fibroblasts contain Cav1.2 channels (Soldatov, 1992, 1994), their amount in aortic tissues 
is far less than that of smooth muscle cells. Therefore, the α11.2 cDNA in aorta is very 
likely to be mainly contributed by aortic smooth muscle cells.  
 
5.7.4 Heart 1-50 cDNA library 
Surprisingly, heart 1-50 has an unexpected exon-combination spectrum not 
described in previous studies. At first, we assumed that the heart 1-50 should be similar 
to aorta 1-50, for there is a highly vascularized system to supply blood and nutrients to 
heart muscles. This study shows the major difference between heart 1-50 and aorta 1-50 
in the distribution of individual alternatively spliced exons was that there were a higher 
representation of exon 8a and a lower percentage of expression of exon 8 in heart 1-50. 
Furthermore, exon 33 was also more abundant in heart 1-50 than that in aorta 1-50 (Table 
4.2, Fig. 4.13). In addition, full-length exon-combinations are strikingly different between 
them (Fig 4.17, Fig. 4.20). Based on these results, it is reasonable to regard heart 1-50 as 
a novel heart cDNA component that has never been reported. In the quantification study 
by Pang et al, exon 1 has been shown to constitute about 10% of the overall α11.2 
transcript in heart tissues (Pang et al., 2003). Presently, we do not have the exact 
knowledge about which cells in heart contain heart 1-50 cDNA. A speculation may be 
made based on the structure of hearts. In normal heart, two thirds of the cell population is 
composed of nonmuscle cells, and the majority of which are fibroblasts, even though they 
account for less than 25% normal myocardial tissue volume (Manabe et al., 2002; 
Chapter V Discussion 
 121
Camelliti et al., 2005). Furthermore, it needs to be noted that Cav1.2 channels are found 
in human skin fibroblast (Soldatov, 1992). Hence, we speculate that heart 1-50 cDNAs 
could be a mixture of cDNAs mainly contributed by cardiac fibroblasts, and partially 
from cardiomyocytes and smooth muscle cells from vascular system in heart tissues. 
However, the exact origins of heart 1-50 cDNA need further experiments to identify. 
 
5.8 Alternative splicing in cardiac and smooth muscle and their 
functional implications 
The distinctions of three cDNA libraries from heart and aortic tissues should 
indicate their functional diversities. The α11.2 subunit of the L-type calcium channel may 
be customized in its proteomic structures to provide for the necessary ability of the 
smooth muscle to contract at physiological voltages. In comparison to the calcium 
channel counterparts found in heart, the voltage-dependence of activation for smooth 
muscle L-type channels exhibited a hyperpolarized shift of -15mV (Nelson et al., 1988; 
Hadley and Lederer, 1991). There is a close correlation between activation potential of L-
type channels and tension in the smooth muscles. The more hyperpolarized activation 
properties of the smooth muscle Cav1.2 channels are required for sufficient tension to be 
generated by modest physiological membrane depolarization. Only a small amount of 
tension would be generated by smooth muscle if the voltage-dependent activation 
potentials of smooth muscle L-type channels were similar to the cardiac Cav1.2 channels.  
Here, we show the dominant exon-combination in cardiomyocytes is (1a, 8a, -9*, 
32, 33, -45*, -45), while the dominant ones in aorta smooth muscle are (1, 8, ± 9*, 21, 32, 
± 33, -45*, -45) (Fig. 4.17). They differ in at least the following 4 regions: (i) exon 1a/1; 
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(ii) exon 8a/8; (iii) ± exon 9*, (iv) exon 21/22 and (v) ± exon 33. The physiological and 
pharmacological functions of these exons have been examined in previous studies by us 
and others. Here, an inclusive view about the impact of the dominant exon-combinations 
from hearts and aortas on tissue specific physiology and pharmacology is discussed. 
  
5.8.1 Impact on physiology 
In the N-terminus, exon 1a has an inhibitive effect on exon 1a-containing Cav1.2 
channels and this inhibitive effect can be relieved through a PKC-mediated effect in 
cardiac muscles (Shistik et al., 1998; Shistik et al., 1999). The significance of exon 1a 
contribution to heart function in physiological context is unknown presently. 
 In addition to the present study, selective high expression of exon 9*-containing 
Cav1.2 channels was identified in the smooth muscle layer of arteries (Liao et al., 2004). 
Exon 9* is located in the I-II loop of the α11.2, immediately downstream of the alpha-
interacting domain (AID). The binding of the β-subunit to the AID modulates Cav1.2 
channel function by enhancing Ca2+ currents and changing the kinetics of the activation 
and inactivation properties of the channel (Walker and De Waard, 1998). However, 
whether the addition of 25-aa encoded by exon 9* may define any binding selectivity of 
the different β-subunits remains to be tested. 
In previous study, we showed that exon 9* shifts the activation potential to a 
hyperpolarized direction by about 10 mV (Liao et al., 2004), and the deletion of exon 33 
(- exon 33) also shifts the activation potential to a hyperpolarized direction by about 10 
mV. Compared to the cardiac exon-linkage, the exon-linkages in aorta has a marked 
increase of exon 9* and decrease of exon 33. Exon 9* is 7-fold increased from 3% in 
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heart 1a-50 to 24% in aorta 1-50 in WKY rats. In addition, expression of exon 33 was 
reduced 41% from 98% in WKY heart 1a-50 to 57% in WKY aorta 1-50, i.e. the deletion 
of exon 33 was increase 41% in aortic tissues. Both changes may act synergically to shift 
the smooth muscle Cav1.2 channels to a more depolarized activation potential. The 
possible physiological relevance is the relationship between activation potential and 
tension. The presence of exon 9* and exclusion of exon 33 hyperpolarized shift the 
activation potential of smooth-muscle L-type Cav1.2 channels, in turn the lowered 
activation potential might allow the influx of calcium current upon slight membrane 
depolarization to produce the required tension in smooth muscles to regulate blood flow 
(Liao et al., 2004). 
 
5.8.2 Impact on pharmacology 
The inclusion of either exon 8 or exon 8a regulates DHP sensitivity. The Cav1.2 
channels containing exon 8 exhibit larger inhibition by DHP nisoldipine when the 
holding potential is -80 mV (Welling et al., 1997). In a similar study, Zuhlke et al showed 
IC50 of isradioine for Cav1.2 channels containing exon 8a is 230 nM while IC50 is 110 nM 
in the channels containing exon 8 (Welling et al., 1997; Zuhlke et al., 1998). One possible 
explanation for this different effects of DHPs on two channels could be due to the 
different affinities of exon 8a or 8 to DHPs, for previous studies have shown the DHPs 
binding affinities correlate well with their efficacy (Sun and Triggle, 1995). However, it 
is well known the high affinity binding sites of DHPs to Cav1.2 channels are located in 
IIIS5, IIIS6 and IVS6 (Peterson et al., 1996; Hockerman et al., 1997; Striessnig, 1999). In 
fact, the Kd values (about 0.1 nM) are similar for isradipine binding to channels of 
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“cardiac form” α1C-a (1a, 8a, -9*, 31) or channels of “smooth muscle form” α1C-b (1, 8, 
9*, 32) (Hofmann F, Biel M, Book, 1994). Hence, the suggestion by Welling et al is that 
IS6 segment which is encoded by exon 8a/8 may involve a “low-affinity” interaction with 
DHPs (Welling et al., 1997). In regard to exon 9*, it does not seem to change the 
nifedipine sensitivity to Cav1.2 channels (Liao et al., 2004).  
In addition, Cav1.2 channels containing exon 22 have also been shown to have a 
higher sensitivity to DHPs than the channels containing exon 21. At a holding potential 
of -90 mV, IC50 for isradipine is 110 nM for exon 22 contained channels and 251 nM for 
exon 21 contained channels. Interestingly, the higher sensitivity of Cav1.2 channels 
containing exon 22 to DHPs seemed to offset the lower sensitivity of Cav1.2 channels 
containing exon 8a. In the same study, Zuhlke et al showed the clone α1c, 105 which 
contains exon-combination (exon 8a + exon 22) have similar IC50 for isradipine (230-250 
nM) when compared to the clone α1c, 70 which contains (exon 8 + exon 21) exon-
combination (Zuhlke et al., 1998).  
In this study we showed the exon linkage (exon 8a + exon 22) is found in about 
62% in of the α11.2 clones in the heart 1a-50 cDNA library while linkage (exon 8 + exon 
21) represent about 75% of the clones in the aorta 1-50 cDNA library (Table 4.3). Hence, 
the difference in IC50 of DHPs between heart 1a-50 and aorta 1-50 would be a 
complicated outcome even only based on the combinations of (exon 8a +exon 22) and 
(exon 8 + exon 21). Therefore, it is purely speculative that the dominant exon-linkages of 
heart 1a-50 (1a, 8a, -9*, 22, 32, 33, -45*, -45) which contains the exon combination 
(exon 8a + exon 22) may have a slightly lower sensitivity of DHPs than the aortic 
dominant  exon-linkage (1, 8, ± 9*, 21, 32, ± 33, -45*, -45) which contains (exon 8 + 
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exon 21). However, this deduced conclusion contrasts with the actual outcome of DHP 
sensitivities detected in pharmacological studies in cardiac and vascular tissues. The 
study on DHPs on native cardiac and vascular tissues revealed a much higher ratio of 
IC50heart/IC50vessel than in vitro under similar membrane potential. The ratios of 
IC50heart/IC50vessel range from 31 to 877 according to the 7 different DHPs (Godfraind et 
al., 1992; Zheng et al., 1992; Sun and Triggle, 1995). Therefore, other factors need to be 
considered. Structures from hearts and vessels are obviously different which may affect 
the binding affinities of DHPs hence the drug sensitivities of two tissues. In addition, the 
underlying mechanisms for tissue-differential DHP sensitivities may also involve the 
altered gating properties and other factors. Especially, it has been shown the DHPs 
sensitivities of Cav1.2 channels are voltage-dependent (Welling et al., 1997; Zuhlke et al., 
1998). Therefore, the combined effect of inclusion of exon 9* and exclusion of exon 33 
on lowering the voltage-dependent activation properties to more hyperpolarized potential 
may be one of the causes. Thus, further experiments are required to test the 
pharmacological properties of Cav1.2 splice variants with α11.2 clones exhibiting the 
exon-combinations revealed in this study. 
5.9 Altered alternative splicing patterns of α11.2 gene in hypertension  
Another major goal of this study is to determine whether a pathological condition 
like hypertension will influence the alternative splicing of α11.2 gene. Our data 
demonstrated that dramatic changes in the splicing profiles of individual alternatively 
spliced exons and in exon-combinations between SHR and WKY rats did occur. These 
changes can be easily identified in certain alternatively spliced exons. Furthermore, due 
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to the alterations in the splicing patterns, there are different and novel exon-combinations 
found in SHR tissues in comparison to those in WKY tissues.  
The most striking difference observed when analyzing the exon-combinations 
between SHR tissues and WKY tissue is that there are 22 aberrant α11.2 splice variants 
found in SHR while only 5 are found in WKY rats. These aberrant variants are derived 
by either inclusion of both mutually exclusive exons like exon 21 and exon 22, or exon 
31 and exon 32, or exclusion of both mutually exclusive exons. To date, no functional 
study has been carried out on such aberrant splice variants. However, it is reasonable to 
think that these proteins with an altered sequence in the transmembrane segments may 
not function properly or are non-functional. Interestingly, aberrant splice variants 
containing (exon 21 + exon 22) were found to be substantially up-regulated in all three 
cDNA libraries from SHR (Fig. 4.29). The correlation of increased expression of aberrant 
splice variants with hypertension suggests that alternative splicing may be prone to error 
under hypertensive stress. 
5.10 Impact of changes in alternative splicing of α11.2 on pathology of 
hypertension 
Even though the mechanism underlying these changes is not clearly understood, 
there is much evidence to show that Cav1.2 splice variants displayed altered gating 
properties and pharmacology. In the following sections, the alterations in individual 
alternatively spliced exons and exon-combinations of the three cDNA libraries are 
discussed.   
 
Chapter V Discussion 
 127
5.10.1 Functional impact of altered splice variations of heart 1a-50 
In spontaneously hypertensive rats with mild or compensated hypertrophy, peak 
L-type Ca2+ currents have been reported to be either unchanged or increased compared to 
age-matched controls (Mukherjee and Spinale, 1998). Furthermore, β-adrenergic 
receptor-mediated augmentation of L-type Ca2+ channel has been demonstrated to be 
generally reduced with hypertrophy, and this mechanism seems to play a substantial role 
in modulation of L-type currents. However, our results in this study suggest the 
differential expression of splice variants of α11.2 subunit in hypertension may also lead 
to the altered functions and regulations of L-type currents. Individual exons like exon 9* 
and exon 32-6nt were found to be up-regulated in SHR heart 1a-50. In the human α11.2 
subunit study, we found both exons would produce channels with lower voltage-
dependent activation potential (Liao et al., 2004; Tang et al., 2004). The inclusion of 
exon 9* in Cav1.2 channels shifts  the activation potential 10 mV in hyperpolarized 
direction while the inclusion of exon 32-6nt results in a 5.3 mV shift in the same 
direction. Therefore, the up-regulation of both exon 9* and exon 32-6nt in SHR hearts 
may partially contribute to the augmented excitation-contraction coupling in hypertrophic 
hearts. Moreover, with a 9% increase in exon 9* and 8% increase in exon 32-6nt, the 
calcium channel population with a hyperpolarized shift activation potential will increase 
to 23% in SHR hearts vs. 6 % in WKY hearts (Table 4.4). However, the resulting 
electrophysiological difference contributed by 17% of this channel genotype may not be 
easily detected in actual hypertrophic cardiomyocytes. Shorofsky et al reported that no 
apparent change in gating properties of Cav1.2 channels based on I-V curve analysis 
(Shorofsky et al., 1999). Interestingly, in a study for human heart failure, a 7.5 mV left 
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shift in failing cardiomyocytes were observed when compared to normal cardiomyocytes 
(Chen et al., 2002). Even though the authors speculated PKA-mediated phosphorylation 
of Cav1.2 channels may underlie this hyperpolarized shift, the idea was challenged by 
Kamp et al. Instead, they proposed that alternative splicing of Cav1.2 channel subunits 
like α11.2, β may be involved (Kamp and He, 2002). It is possible that the alteration in 
expression of α11.2 splice variants as identified in hypertension may be similar in the 
formation process of heart failure, and this alteration leads to the changes in Cav1.2 
channel gating properties. 
Another possible outcome of the alteration of α11.2 splice variations in heart 1a-
50 under hypertensive condition could be the prolonged action potential duration (APD) 
which is often observed in hypertrophic cardiomyocytes (Ahmmed et al., 2000). It is 
believed that Cav1.2 channels with a lowered activation potential threshold would 
enhance the influx of calcium currents in response to stimuli, and that in turn will  
increase intracellular calcium concentration to prolong cardiac action potentials. 
However, it needs to be noted that other factors like membrane capacitance, cell volume, 
K+ current et al can also affect the shape of cardiac action potential, and all these factors 
have been known to be altered in SHR hearts (Padmala and Demir, 2003).  
     
5.10.2 Functional impact of altered splice variations of heart 1-50 
As mentioned before, heart 1-50 cDNA is speculated to be a mixture of cDNAs 
possibly contributed by cardiac fibroblasts, cardiomyocytes and smooth muscle cells of 
the vascular system of the heart. Due to the uncertain origin of this cDNA, it is difficult 
to speculate on the functional impact of alteration in heart 1-50 cDNA. However, two 
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changes in SHR heart 1-50 cDNAs should be highlighted. The 16% up-regulation in exon 
8 may affect the pharmacological effects of DHPs on these channels (Welling et al., 
1997). Furthermore, heart 1-50 cDNAs provide a comparative perspective to understand 
the alternative splicing of α11.2 subunit in hypertension in SHR. Evidence shows changes 
in the pattern of alternative splicing of heart 1-50 cDNAs not only in the usage of 
individual alternatively spliced exons but also in the combinatorial splicing patterns in 
SHR. At the individual exon level, only altered ratios of expression of exon 8a and exon 
8 were found. However, a detailed examination of exon-combinations revealed that the 
alternative splicing patterns were dramatically changed in SHR heart 1-50 cDNAs. 
Extraordinarily, an aberrant splice variant V33 (1, 8a, -9*, 21, 22, 32, 33) was generated 
in SHR but not in WKY rats. Even though V33 contains both mutually exclusive exon 21 
and 22 and may not function properly, this splice variant may serve as an indicator to 
monitor the progress of heart remodelling under hypertensive conditions. The functional 
significance for the upregulation of V33 expression in hypertension requires future 
experiments for answers.  
 
5.10.3 Functional impact of altered splice variations on the vascular system 
Alterations in vascular structure are common in hypertension. Two processes, 
vessel remodelling and/or vessel hypertrophy, are responsible for these changes in arterial 
structure. Vessel remodelling occurs through reorganization of apparently existing 
cellular and extracellular components around a smaller lumen.  In contrast, hypertrophy 
involves vascular smooth muscle cell (VSMC) proliferation, hypertrophy, and/or 
polyploidy. (Ueno et al., 2000).  
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In SHR aortas, exon 9* and exon 33 were up-regulated by 14% and 18% 
respectively. It is reasonable to consider these changes mainly found in smooth muscle or 
fibroblasts in remodelling aortas. Being different from normal aortas, aortas under 
hypertensive stress demonstrate structure remodelling and hypertrophy, in which smooth 
muscle cells and fibroblasts are supposed to be actively involved (Intengan and Schiffrin, 
2001). The physical continuity of the vascular system suggests that changes in aorta are 
very likely to happen to the muscular arteries as well. In previous study, we showed exon 
9* shifted the activation potential in a hyperpolarized direction by about 10 mV, while 
exon 33 shifted the activation potential in a depolarized direction by about 10 mV (Liao 
et al., 2004; Tang et al., 2004). Therefore, one possible outcome for increased expression 
of both exons in Cav1.2 channels may be that the direction of activation potential shift is 
unaltered if the expression of exon 9* and exon 33 are coordinated. However, another 
outcome could also be the lowered activation potential in smooth muscles in SHR aortas 
due to the different distribution of exon 9* and exon 33 in different cells. For example, 
exon 9* may be mainly up-regulated in smooth muscle while exon 33 is mainly up-
regulated in fibroblasts or verse versa. Till now, the insertion of exon 9* and deletion of 
exon 33 both have been identified in fibroblasts in our laboratory, and this lends supports 
to the above assumption. If the overall outcome is the latter, then the higher population of 
Cav1.2 channels with lowered activation threshold in SHR aortas may contribute to 
stronger contractions of smooth muscles in hypertensive phenotypes. The more 
depolarized resting membrane potential of arterial smooth muscle may serve to facilitate 
the activation of the Cav1.2 channels with lowered activation threshold after sympathetic 
stimulation or elevation of intravascular pressure (Jaggar et al., 1998). This process 
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would contribute to Ca2+ influx that presumably triggers greater myogenic tone or more 
prolonged contraction of the blood vessels, and thereby produce the higher blood 
pressure in hypertensive phenotypes. 
There were some studies which reported a more hyperpolarized activation 
potential found in SHR. For example, Matsuda K et al showed current-voltage curves 
were shifted toward more negative voltages in SHR compared to WKY in rat mesenteric 
arteries (Matsuda et al., 1997). However, Simard et al reported no change in channel 
gating properties was found in Goldblatt 2-kidney 1-clip (2K1C) hypertensive rat model 
(Simard et al., 1998).  
5.11 Possible mechanisms underlying tissue-specific exon-combinations 
The striking differences in exon-combinations of the rat α11.2 gene exhibited in 
the 3 cDNA libraries derived from heart and aorta raise an important question about how 
tissue specific splice variations are generated. 
The underlying mechanisms directing tissue specific alternative splicing is still 
largely unknown. In this study, the distinct splicing patterns (linkages) were found in 
three cDNA full-length libraries containing either exon 1a or exon 1 as the first exon in 
heart tissues, and only exon 1 in aortic tissues. Since the distinct exon-combinations 
involving so many alternatively spliced exons in three cDNA libraries were first time 
revealed, no previous knowledge is available to the exact answer for the regulation of 
tissue-specific alternative splicing patterns in α11.2 gene. Here, we propose two 
conceptual explanations which are discussed in following. 
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On one hand, the distinction of splicing patterns of α11.2 gene in heart and aorta 
may be partially explained by the transcription- splicing coupling hypothesis (Maniatis 
and Reed, 2002) (Kornblihtt et al., 2004). Numerous recent studies in metazoans have 
provided compelling evidence that transcription can affect splicing (Auboeuf et al., 2002; 
Kadener et al., 2002). For exon 1a and exon 1, they are activated by different promoters 
(Pang et al., 2003). Studies showing that transcription of pre-mRNA by different 
promoters can generate different alternatively spliced mRNAs (Cramer et al., 1997; 
Cramer et al., 1999). Two models which are not mutually exclusive have been proposed 
to explain this promoter-specific alternative splicing. In the first model, particular SR 
proteins are differentially recruited to promoters and are then handed off to cognate 
splicing enhancers to promote inclusion of specific exons in the mRNA. In the second 
model, the pattern of splicing is determined by the rate of elongation in the transcription 
process that in turn is dictated by the particular promoter (Goldstrohm et al., 2001; 
Maniatis and Reed, 2002). Therefore, the distinct splicing patterns between heart 1a-50 
and heart 1-50 may be partially explained by this transcription-splicing coupling theory.  
On the other hand, the different splicing patterns of heart 1a-50, heart 1-50 and 
aorta 1-50 may be due to cell-type specific or tissue-specific alternative splicing 
mechanisms. It is known that ubiquitous RNA-binding proteins are implicated generally 
in alternative splicing. Nonetheless, a number of specific regulatory proteins are 
expressed only in certain tissues. These proteins regulate alternative splicing of specific 
sets of pre-mRNAs (Maniatis and Tasic, 2002). For example, a pan-neuronal pre-mRNA-
binding protein Drosophila ELAV binding to neuroglian pre-mRNA results in alternative 
inclusion of a neural-specific terminal exon (Toba et al., 2002). At present, there are only 
Chapter V Discussion 
 133
a few examples of proteins that regulate tissue-specific alternative splicing, but it is likely 
that tissue-specific alternative splicing of α11.2 subunit could be another example. 
5.12 Possible mechanism underlying the alteration of alternative 
splicing profiles in hypertension 
 It is well known in hypertensive animals or patients, cardiac hypertrophy is a 
common outcome (Pinto et al., 1998). The signalling pathways involved in cardiac 
hypertrophy are multifactorial. These signals involve biochemical stress like 
neurohumoral stimulations and hemodynamic stress like high blood pressure. Different 
splicing patterns in SHR vs. WKY rats could be governed by distinct inductions of 
differential alternative splicing triggered by normal or pathological signals. However, the 
detailed pathways for regulation of alternative splicing of α11.2 gene by hypertensive 
signals remain unsolved.  
 In aortas, the increased blood pressure has been shown to enhance the influx of 
calcium ions and activate α11.2 subunit transcription. One of the underlying mechanisms 
for this process could be due to the more depolarized membrane potentials observed in 
hypertension (Pinto et al., 1998; Fan et al., 2000; Wellman et al., 2001; Pesic et al., 
2004). The increased influx of calcium ions and upregulated transcription of α11.2 
subunit have been confirmed in many other hypertensive models (Simard et al., 1998; 
Callera et al., 2001). The consequential increase of intracellular calcium concentration 
[Ca]I and the activation of following signalling pathways may be involved in the 
regulation of the alternative splicing of α11.2 gene. A notable example of regulation of 
alternative splicing by influx of calcium current is the regulation of the exclusion of 
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STREX exon by stress signals, where depolarization of pituitary cells activates CaMK IV 
by the influx of calcium currents through calcium channel (Xie and McCobb, 1998; Xie 
and Black, 2001).  
  
5.13 Implications of alternative splicing of α11.2 gene in hypertension  
Alternatively spliced exons that expressed differentially under hypertensive 
conditions may be used as biomarkers for hypertension. For example, the combination 
(exon 21+exon 22) may be an indicator of certain kinds of hypertension. More 
experiments are needed to generalize the association of increased expression of (exon 
21+exon 22) with other types of hypertension. In addition, understanding the underlying 
mechanism for alternative splicing of Cav1.2 channels in response to hypertension will 
help significantly in rationalizing the cause and effect of α11.2 structural changes to their 
functional implications in hypertension.  
There may be a reciprocal correlation between hypertension and alternative 
splicing of α11.2 gene. On one hand, hypertension causes the changes of alternative 
splicing of α11.2 gene; on the other hand, it is possible that some splice variants of α11.2 
gene may aggravate the development of hypertension, since there are many cases in 
which misregulation of alternative splicing cause diseases (Grabowski and Black, 2001). 
This hypothesis should be tested in future study. 
5.14 Advantages and limitations of the study 
 There are several advantages to assess alternative splicing in full-length cDNAs 
over other methods. It is not possible to analyze overlapping fragmental PCR products to 
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reconstruct the combinatorial arrangement of alternatively spliced exons. Similarly, 
traditional cDNA library screening method would normally yield partial cDNAs or a 
limited number of full-length clones of α11.2, which will be unsuitable for statistical 
analysis or comparative studies in a meaningful way. However, there are some limitations 
in using full-length cDNA libraries. Full-length PCR products larger than 5 kb are 
generally difficult to be amplified and are cumbersome to be cloned. As a matter of fact, 
the bottle neck in this study was to get enough clones containing full-length α11.2 cDNA. 
 We have managed to isolate 689 full-length clones after screening 4000 colonies. 
Each of the 6 different cDNA library contained about 100 clones. As shown in Fig. 4.18, 
the exon-combinations varied from 10 ~ 36 in different libraries. Furthermore, some 
exon-combinations are dominant and some are minor. Therefore, many full-length exon-
combinations found in this study are represented in 1-4 clones (Table 4.4), and these low 
numbers of counts are not amenable to statistical analysis. Therefore, only dominant 
exon-combinations and clones with a percentage higher than 5% were compared in this 
study. Ideally, each cDNA library should contain about 500 clones in order to 
meaningfully compare exon-combinations of clones that represent as little as 1% of the 
total population. 
 Another limitation of this study is that only one type of genetic hypertensive 
model (SHR) was tested. For more generalizable results about the alternative splicing of 
α11.2 under different types of hypertension, other hypertensive models like 2-kidney, 1-
clip model, aortic-banded model, and Dahl salt-sensitive rats et al should also be 
analyzed in future studies. 
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 There are limitations in tissue selections in this study as well. Being a preliminary 
attempt to search for the relationship of alternative splicing of α11.2 gene and 
hypertension, our present study only concentrated on heart and aorta for a glimpse of 
changes in the cardiovascular system. An extensive study on small arteries is warranted 
in future study since the contraction of small arteries directly affects the blood pressure.  
5.15 Future Study 
The present study serves as a first step to understand the complexity of alternative 
splicing of the α11.2 subunit in different tissues under normal and hypertensive 
conditions. This work has opened up many more questions and hypotheses that future 
experiments may provide appropriate answers.  
One area for future study to determine the patterns of alternative splicing of α11.2 
subunit should be carried out in a single cell and for various cell types, instead of in a 
mixed population of cells found in tissues. This could help dissect the exon-linkages and 
exon-combinations in different types of cells. The 5 exon linkages and 64 splice variants 
identified in this study are extracted from heart and aortic tissues. Therefore, this 
diversity could be due to different types of cells containing Cav1.2 channels. At least in 
heart, cardiomyocytes, smooth muscles from blood vessels and cardiac fibroblasts have 
been shown to contain Cav1.2 channels. Although heart 1a-50 cDNA is mainly expressed 
in cardiomyocytes, the origin of heart 1-50 cDNA is poorly understood. It could be 
derived from any type of the three cells, or the situation may be even more complicated 
and aorta 1-50 cDNA could be generated from mRNA extracted from a mixture of 
vascular smooth muscles and fibroblasts. Hence, the knowledge of alternative splicing of 
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the α11.2 gene in different types of cells will be valuable to differentiate the cell-specific 
expression of the 64 splice variants, and the prediction of their functional significance 
may be made easier. Especially in the hypertensive model, the precise identification of 
changes of the splicing profiles of the α11.2 gene in a cell type would be helpful toward a 
better understanding of the pathological process.  
 On one hand, further studies are needed to gather a more complete view of the 
functional correlation between differential alternative splicing patterns in different 
tissues. The pathways about tissue specific regulations of α11.2 subunit should be 
identified in detail. Three dramatically different full-length α11.2 cDNA libraries 
demonstrate that α11.2 subunit is a good target to work with. The outcome will contribute 
significantly to our understanding of the regulation mechanism in tissue-specific 
alternative splicing.       
On the other hand, it is significant to understand the alternative splicing of α11.2 
subunit under hypertensive conditions and other cardiovascular diseases. Here, our 
preliminary data show dramatic differences in the expression and distribution of splicing 
profiles in three full-length α11.2 libraries of the SHR and WKY rats. This suggests that 
future studies on alternative splicing of Cav1.2 channel should look for the causes for 
altered splice patterns. In addition, studies focused on small arteries should be carried out 
to find the reciprocal effects of alternative splicing of α11.2 gene in smooth muscle cells 
and the elevated blood pressure. One good example which can be further explored is the 
stroke prone-SHR (SHR-SP) model of the same rat strain. 
As well, many exon-combinations which can be inferred from theory and now 
confirmed in reality should be the targets for functional studies and pharmacological 
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tests. The overall 64 splice variants of α11.2 identified in this study provide a rich 
resource to dissect their functional characteristics and the effects of known drugs like 
dihydropyridines (DHPs), phenylakylamines (PAAs), and benzothiazepines (BTZs). 
Furthermore, the predominant splice variants should be chosen for future drug screening 
for antagonists or agonists targeting Cav1.2 channels. For example, in order to find drugs 
for Cav1.2 channels in cardiomyocytes, the presumably preferred dominant splice 
variants containing exon 1a like V1 (1a, 8a, -9*, 22, 32, 33,-45*,-45) and V2 (1a, 8a, -9*, 
21, 32, 33, -45*, -45) could be used; on the other hand, if a drug is designed to block the 
Cav1.2 channel from vascular smooth muscles, then the dominant splice variants from 
aorta exon 1-50 cDNA library like V21, V28, V27 and V18 could be more appropriate 
(Fig 4.17, Table 4.4). Since the origins of heart 1-50 cDNA are not defined thus far, the 
splice variants in this cDNA library may become useful after we determine their exact 
localization. 
In a broader extent, the alternative splicing of other subunits like β, α2δ should be 
investigated to provide a complete view for the alternative splicing of the entire Cav1.2 
channel complex. Furthermore, to go beyond the cardiovascular system, in brain and 
endocrine tissues where Cav1.2 channels play important roles, similar study for searching 
altered splicing variants under pathological conditions could be carried out. 
5.16 Conclusions  
 The hypothesis that alternative splicing serves as an elegant means to diversify the 
proteomic functions has been fully demonstrated in this study. The study of alternative 
splicing of human α11.2 gene by transcription-scanning method revealed 19 out of 55 
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exons are subjected to alternative splicing. Among these 19 exons, two novel exons exon 
9* and exon 10* are identified in human tissues. Exon 9* has been shown to be expressed 
selectively in vascular smooth muscle. In addition, insertion of exon 9* in full-length 
α11.2 gene produced channels with more hyperpolarized activation potentials. However, 
the properties of exon 10* containing Cav1.2 channels are still unknown. Detailed 
analyses of the distribution of splice variations in IVS3-IVS4 region revealed tissue 
specific and development-dependent regulation. Furthermore, electrophysiological study 
demonstrates an interesting correlation between the linker length in IVS3-IVS4 region 
and the activation potential. The relationship could be summarized as the longer the 
linker length, the more depolarized the activation potential.  
In the study of alternative splicing of α11.2 gene in rat heart and aortic tissues, 
exon-combinations are found to be generally linked and uncoordinated. A total of 64 full-
length exon-combinations have been found in rat heart and aortic tissues based on 10 
alternatively spliced exons. In addition, three distinctive full-length cDNA libraries have 
been generated. Two are from hearts which are heart 1a-50 and heart 1-50 cDNA 
libraries, while only one aorta 1-50 cDNA library is found in aortas. Comparative study 
shows the dramatic difference in ratios of individual alternatively spliced exon as well as 
distinct exon-combinations among the three cDNA libraries. Therefore, for the first time, 
a comprehensive tissue specific alternative splicing patterns are revealed in the α11.2 
gene. Surprisingly, heart 1-50 cDNAs have not been reported previously. The origin of 
this component is not clear now and further experiments are needed to determine their 
localization. The tissue-specific alternative splicing patterns are believed to underlie the 
tissue-specific functional diversity of Cav1.2 channel in the heart and vascular systems.  
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The comparative study carried out on SHR and WKY rat tissues showed that 
under hypertensive conditions, the alternative splicing of α11.2 gene is also significantly 
altered. Especially, it seems alternative splicing of α11.2 gene is prone to error under 
hypertensive stress. Therefore, more aberrant splice variants which may encode non-
functional channels are found in SHR than in WKY rats. However, the molecular 
mechanism underlying the change is unknown.  
Some compelling questions on the role of alternative splicing of calcium channel 
in physiology await future research to provide the answers. The biological role of a 
particular alternatively spliced exon of the α11.2 subunit is unknown. Nonetheless, it is 
conceivable that with mouse knock-out and knock-in techniques, their functional roles 
may be revealed in the near future. Equally fascinating is the understanding of what 
directs alternative splicing and what factors regulate the specific expression of 
alternatively spliced exons spatially, temporally and in disease.  
It is evident that alternative splicing is an exquisite mechanism that operates to 
diversify Cav1.2 channel structures by the combinatorial inclusion or exclusion of 
alternatively spliced exons. The 64 full-length splice variants of α11.2 subunit found in 
rat heart and aorta will contribute to the numerous proteomic variations of the Cav1.2 
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